



Quantification of Antiretroviral Medicines Requirements for the Botswana Central Medical Stores – 2007 to 2009

Report on Quantification Technical Assistance to the Central Medical Stores of Botswana under US Government-funded Technical Assistance

September 2007

Rafiu Adeyemi Idris, ACTS Advisor, SCMS Namibia
Francis Aboagye-Nyame, Country Program Manager, SCMS



Providing quality medicines for people living with and affected by HIV and AIDS



Quantification of Antiretroviral Medicines Requirements for the Botswana Central Medical Stores – 2007 to 2009

Report on Quantification Technical Assistance to the Central Medical Stores of Botswana under US Government-funded Technical Assistance

September 2007

Rafiu Adeyemi Idris, ACTS Advisor, SCMS Namibia
Francis Aboagye-Nyame, Country Program Manager, SCMS



Providing quality medicines for people
living with and affected by HIV and AIDS



Acknowledgements

We wish to express our thanks to Stanley Mapiki and the rest of the SCMS Botswana office for their warm hospitality and facilitation of this exercise. Also many thanks to Lydia Zungufya who collected and processed initial data received from ART facilities in the country. Our gratitude also go to Mrs. Baile Moumakwa of Central Medical Stores and her team who supplied valuable information for the quantification exercise and Mr. Emmanuel Molesiwa and the staff of Princess Marina Hospital, Gaborone for the warm reception and useful discussions we had.

About SCMS

The Supply Chain Management System (SCMS) was established to enable the unprecedented scale-up of HIV/AIDS prevention, care and treatment programs in the developing world. SCMS procures and distributes essential medicines and health supplies, works to strengthen existing supply chains in the field, and facilitates collaboration and the exchange of information among key donors and other service providers. SCMS is an international team of 16 organizations funded by the US President's Emergency Plan for AIDS Relief (PEPFAR). The project is managed by the US Agency for International Development.

This document was made possible through support provided by the US Agency for International Development, under the terms of contract number GPO-I-00-05-00032-00. The opinions expressed herein are those of the author(s) and do not necessarily reflect the views of the US Agency for International Development or the US government.

Recommended Citation

Idris, R.A., Aboagye-Nyame, F. 2007. *Quantification of Antiretroviral Medicines Requirements for the Botswana Central Medical Stores – 2007 to 2009*. Submitted to the Botswana Ministry of Health by the Supply Chain Management System (SCMS).

This document may be reproduced if credit is given to SCMS.

Supply Chain Management System

1616 Ft. Myer Drive, 12th Floor
Arlington, VA 22209 USA
Telephone: +1-571-227-8600
Fax: +1-571-227-8601
E-mail: scmsinfo@pfscm.org
Website: www.scms.pfscm.org

Table of Contents

Table of Contents	i
Acronyms	ii
Introduction.....	3
Background	3
Objectives.....	4
Botswana ART Program	4
Supply Chain Management of ARVs	5
Quantification.....	7
Scope of Forecast.....	7
Methodology	8
Data Inputs and Key Assumptions	9
Quantification Results	16
Supply Plan.....	18
Findings and Recommendations	21
Findings	21
Recommendations.....	22
Appendix 1: CMS and SCMS Prices	24
Appendix 2: Pipeline Stock Status Report	27
Appendix 3: List of Regimens by Condition and Category.....	56
Appendix 4: Regimen Episodic Costs	64

Acronyms

ADT	Anti-Retroviral Dispensing Tool
AIDS	Acquired immunodeficiency syndrome
ANC	Ante Natal Care
ART	Anti- Retroviral Therapy
ARV(s)	Anti – Retroviral(s)
CHAI	Clinton HIV/AIDS Initiative
CMS	Central Medical Stores
GFATM or GF	Global Funds HIV/AIDS,TB and Malaria Programme
HAART	Highly active antiretroviral therapy
HIV/AIDS	Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome
LMIS	Logistics Management Information System
MASA	Botswana National ARV Therapy Programme
MOH	Ministry of Health – Botswana
MOLG	Ministry of Local Government
MOS	Months of Stock
NACA	National AIDS Control Agency
PEPFAR	US President’s Emergency Plan for AIDS Relief
PLWHA	People Living with HIV/AIDS
PMTCT	Prevention of Mother-to-Child Transmission
SCMS	Supply Chain Management System
SOH	Stock on Hand
UNITAID	International Drug Purchase Facility
WHO	World Health Organization

Introduction

Background

The Central Medical Stores (CMS) of Botswana is a Ministry of Health (MOH) institution charged with the responsibility for managing the supply chain for all health commodities supporting all institutions under the Ministry of Health, Ministry of Local Government, Mine and Mission – both public and private. CMS is also the institution managing the supply chain for all commodities needed for HIV prevention, care and treatment in support of the government HIV/AIDS program. The Botswana National ARV Therapy Programme (MASA) is the premier Government of Botswana program whose goal is to ensure universal access to HIV care and treatment services to citizens of Botswana who require them. The program is supported and funded by various partners including the Government of Botswana, United States President's Emergency Plan for AIDS Relief (PEPFAR), Boehringer Ingelheim and the Bill and Melinda Gates Foundation in partnership with Merck Foundation.

The Botswana government is committed to providing ARVs to the citizenry living with HIV/AIDS through its national ARV (MASA) program. In a MASA presentation in 2001, it was estimated that 150,000 People Living with HIV/AIDS (PLWHA) would be put on treatment by December 2009. However these targets have subsequently been revised to a target of 95,000 by March 2008, 110,000 by March 2009 and 125,000 by March 2010. A MASA monthly report released at the end of June 2007 showed that 79,990 PLWHA are already on treatment in the public sector, with 7.82 percent (6,258) out of this number under the government public private partnership arrangement for private sector patients. This program is supported by development partners like PEPFAR, Clinton HIV/AIDS Initiative (CHAI) and Global Fund.

To ensure continuity of supply, there is the need to carry out a national forecast of ARVs and related commodities, the development of a procurement plan and the subsequent mobilizing of required resources. In line with building capacity of staff of the MOH, there is also a need to train CMS and other MOH staff in forecasting and procurement planning using SCMS available software tools so that these trained persons can transfer the knowledge and skills to others within the supply chain from all participating treatment sites. This will facilitate the achievement of sustainable and universal access to all patients who require ARVs.

The Supply Chain Management System (SCMS) was established as part of PEPFAR to support the rapid scale-up of HIV/AIDS prevention, care and treatment. SCMS's mission is to strengthen or establish secure, reliable, cost-effective and sustainable supply chains to meet the care and treatment needs of people living with or affected by Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS). SCMS's broad team of public and private sector organizations supports the strengthening of supply chains to deliver a continuous flow of high-quality, affordable, life-extending medicines and supplies throughout the developing world.

In Botswana, the SCMS Project with support of the US Government through the Botswana Ministry of Health and the US Centers for Disease Control and Prevention (CDC) collaboration (BOTUSA)

is providing technical assistance and support to strengthen supply chain management systems in support of the national HIV/AIDS program. As part of this mandate, SCMS is providing technical assistance and support to the Central Medical Stores of Botswana for the development of modern logistics practices and technologies to efficiently carry out its responsibility of procurement, quality assurance, storage and distribution of HIV/AIDS-related commodities for all government, mission, mine and non-government organizations in Botswana and also supporting the setting up of a central coordination mechanism for national level forecasting, quantification and procurement planning for MOH, BOTUSA and other donor-funded HIV/AIDS-related commodities, through the development of 24-monthly procurement plans in collaboration with MOH, MASA, Ministry of Local Government (MOLG), BOTUSA and other relevant stakeholders, that will be updated quarterly to inform the procurement of commodities.

This quantification exercise is therefore undertaken as part of the activities planned to accomplish the goals stated above in collaboration with the CMS and MASA. This initial quantification will set the stage for the establishment of a national mechanism for regular updates of a national forecast and supply plan for ARVs, which will contribute to ensuring a continuous supply.

Objectives

The main goals of the quantification exercise were to:

- Develop an evidence based forecast of ARV requirements to support the national HIV/AIDS program for the 2007 to 2010 program years
- Develop a 24-month procurement and supply plan taking into consideration service capacity and all funding sources
- Identify any supply gaps and under funded categories
- Identify constraints in data management to support regular forecasting and supply planning
- Develop recommendations for institutionalization of a formal HIV/AIDS pipeline monitoring system capable of conducting quarterly updates of forecast and supply plan

Botswana ART Program

In 2002 the Botswana Government introduced a nationwide antiretroviral therapy program which provided free access to anti-retroviral (ARV) drugs to the citizens of Botswana (including their foreign spouses). Provision of the free treatment was built around an “ART Site” model consisting of a hospital supported by satellite screening clinics. To date all hospitals – Infectious Disease Control Clinics (IDCCs) – in Botswana offer ARV services which range from testing, ARV prescribing, ARV dispensing and CD4 and viral load monitoring. The satellite clinics provide variable ARV services and at least 30 clinics now offer these services fully. The Ministry of Health and the Ministry of Local Government have joint responsibility for the provision of Health Services with support from partners including BOTUSA, African Comprehensive HIV/AIDS Partnerships (ACHAP), Clinton Foundation and Harvard University.

By the end of June 2007, there were 89,504 patients on HAART in Botswana of which approximately 73,732 were public sector patients treated in public facilities, 6,258 public sector patients out-sourced to private facilities under a Public Private Partnership arrangement and 9,514 patients treated in the private sector by Medical Aid Schemes, and work-place programs. The MASA scale up plan is to rollout ARV therapy to 125,000 patients by March 2010. Furthermore, the ARV treatment guidelines are being revised to bring them in line with international practice.


All the 73,732 public sector patients receive their medications through the Central Medical Stores (CMS) system and sites faced with appreciable human and technological challenges.

Supply Chain Management of ARVs

The provision of ARVs for the MASA Program has been the responsibility of the Botswana Government with approximately 10% support from PEPFAR. Other donors such as the ACHAP program provide commodities in kind. For example the Bill and Melinda Gates Foundation has contributed ARVs such as Efavirenz and Indinavir while The Clinton Foundation proposes to provide pediatric formulations and drugs for second line treatment.

The Central Medical Stores of Botswana is responsible for the procurement and supply chain management of ARVs. This includes responsibility for forecasting and quantification, monitoring of supply plans and procurement for both the government and PEPFAR funded drugs. In addition CMS provides warehousing, quality assurance and distribution of ARVs to all public health sites countrywide. A number of stakeholders play important roles in the management of ARVs and HIV/AIDS commodities in general in Botswana. These include the Drug Regulatory Unit (DRU), the MASA program, the Ministry of Local Government and the Public Procurement and Assets Disposal Board. Figure 1 below provides a description of the various stakeholders and partners in the supply chain management of ARVs in Botswana.

Figure 1: Financing, Procurement and Distribution of ARVs



CMS distributes ARVs on monthly basis to all 32 ART sites and also provides commodities to the Disease Management Company which distributes to its client sites on a named patient basis, under the government out sourced program. Sites are expected to place their ARV orders monthly and also provide reports on usage and other service data to MASA. Reports from sites are not consistently submitted and this poses a big challenge to the CMS ARV supply chain management. For example as at June 2007, only 18 out of the 32 pharmacy sites are able to consistently provide monthly reports to MASA and CMS.

Quantification

Scope of Forecast

The scope of the quantification and forecast was national, covering all programs and funding sources. The commodities to be quantified for included ARVs as specified in Table 1 below. The forecast and supply plan covers the period July 2007 to December 2009.

Table 1: List of ARVs Forecasted

S/N	Product	Unit of Issue	Pack Size	Price Per Pack ¹ (BWP)
1	Abacavir [Ziagen] 20mg/ml	ml	240 ml	31.32
2	Abacavir 300mg	tab	60 tabs	72.90
3	Didanosine [Videx] 100mg	tab	60 tabs	89.89
4	Didanosine [Videx] 50mg	tab	60 tabs	95.63
5	Didanosine 100MG	tab	60 tabs	89.89
6	Didanosine 25MG	tab	60 tabs	84.30
7	Didanosine EC [Videx EC] 400mg	cap	30 caps	23.67
8	Didanosine EC 250mg	cap	30 caps	22.50
9	Efavirenz [Stocrin/Sustiva] 50mg	cap	30 caps	3.47
10	Efavirenz 200mg	cap	90 caps	16.00
11	Efavirenz 600mg	tab	30 tabs	12.42
12	Lamivudine 10mg/ml	ml	240 ml	6.73
13	Lamivudine 150mg	tab	60 tabs	5.70
14	Lamivudine-Zidovudine 150+300mg	tab	60 tabs	18.50
15	Lopinavir-Ritonavir [Aluvia] 200+50mg	tab	120 tabs	41.10
16	Lopinavir-Ritonavir [Kaletra] 80+20mg/ml	ml	300 ml	41.10
17	Nevirapine [Viramune] 10mg/ml	ml	240 ml	155.25

¹ Source of Prices: CMS June 2007

S/N	Product	Unit of Issue	Pack Size	Price Per Pack ¹ (BWP)
18	Nevirapine 200mg/tab	tab	60 tabs	186.30
19	Ritonavir 100mg/cap	cap	84 caps	9.59
20	Saquinavir [Invirase] 200mg	cap	270 caps	474.35
21	Stavudine [Zerit] 15mg	cap	60 caps	16.24
22	Stavudine [Zerit] 1mg/ml	ml	200 ml	10.07
23	Stavudine 1mg/ml	ml	200 ml	10.07
24	Stavudine 20mg/cap	cap	60 caps	33.67
25	Stavudine 30mg	cap	60 caps	33.14
26	Tenofovir disoproxil fumarate 300mg	tab	30 tabs	128.84
27	Zidovudine [Retrovir] 10mg/ml	ml	240ml	7.10
28	Zidovudine [Retrovir] 300mg	tab	60 tabs	17.40
29	Zidovudine 100mg	cap	100 caps	15.77

Methodology

The morbidity method was adopted as the most appropriate methodology for the forecast of ARV requirements for the ART program. This was because the ARV program is in a scale-up mode and accurate data on consumption is not available. In addition, since full supply or steady state status has not yet been attained in the program, and there is the potential for changing regimens, and switches of regimens, past consumption data will not be a very good indicator of the future requirements.

Analysis of facility level data was done using Microsoft Excel and Quantimed® was used as the quantification tool for the forecast since it is the preferred tool for morbidity based quantification, and PipeLine® was used to develop the supply plan.

Data Inputs and Key Assumptions

Data Sources

Data on ART regimens and clients were collected from the MASA program, two referral hospitals – Princess Marina in Gaborone and Nyangabwe in Francistown – and other ART sites and aggregated into formats that could be used to derive the required quantification data entry parameters.²

Other sources used for the forecast are:

- a. MASA presentation on the HIV/AIDS situation in Botswana, 2001
- b. MASA HAART Patient Uptake Summary, June 2007
- c. Botswana ART Guidelines, 2005
- d. ARV price list and pack sizes from CMS
- e. ART regimen and ARV use data collected from all ART sites in the country extracted from MASA databases

The data available was based on medicines and medicine combinations rather than regimens as required for use in Quantimed®, thus an analysis was done to generate the required assumptions and data elements.

For this exercise, the ART population was divided into three groups to accommodate the varying characteristics of the populations. The three groups were Princess Marina Hospital, Nyangabwe Hospital and all other ART sites as one group.

Key Assumptions

The quantification of ARVs was based on targets set by the MASA program. The main sources of data for the exercise were the MASA presentation on the HIV/AIDS situation in Botswana 2001, and the MASA HAART Patient Uptake Summary, June 2007. It was noted that there is a proposed new ART guideline yet to be implemented; however, it was not clear the exact time that the new protocol was to take effect. The following assumptions were used for the exercise:

1. The ART client population as at June 30, 2007 was 79,990. This comprises 73,732 clients in public institutions and 6,258 clients in private institutions.³ Table 2 provides a breakdown of the patient numbers by facility.

Table 2: Total Patients on Treatment at All Public Sector Supported ART Sites: June 2007

Site	Public	Out Sourced	Total
Princess Marina Hospital	13,977	2,604	16,581
Nyangabwe Hospital	8,910	1,713	10,623
Other ART Sites (30)	50,845	1,941	52,786
Total	73,732	6,258	79,990

² Required data elements include number of patients on treatment; number of adults and pediatrics, number of 1st and 2nd line treatment, percentage of patients on each regimen

³ HAART Patient Update Summary. June 2007. M & E Unit, MASA

2. It was noted that a new protocol has been proposed which is due to come into effect, however, since the exact transition plan was not clear at the time of the quantification, it was assumed that the current regimens and age distribution will be maintained throughout the forecast period. The required adjustments will have to be made when the transition plan is finalized.
3. ARV dosage regimens are according to the current Botswana ART guidelines
4. The regimen distribution in new clients will be the same as in existing clients
5. Prices used for valuation are current CMS prices and are assumed to hold constant throughout the forecast period. Current SCMS prices are also used for comparison. Where there is no CMS price for a product, SCMS prices are used
6. The forecast period is from June 2007 to December 2009
7. Five percent overage will be added to tablets/capsules and seven percent added to syrups on the assumption that additional needs will be necessary to cater for the following scenarios
 - Losses from medicine expiration, spillage and inappropriate prescription and use
 - Accommodating the need to draw and/or dispense slightly more doses than required for liquid preparations
8. Post exposure prophylaxis

There is no data on PEP coverage to base assumptions on. Therefore the overages allocated above are assumed to take care of PEP needs.
9. The ART population scale up rate used was based on an initial ART patient population of 79,990 as at the end of June 2007, assumed to increase linearly to attain the national target of 95,000 by March 2008, 110,000 by March 2009 and 125,000 by March 2010.

Table 3: Current and Target Patient Numbers

Site	Patient Group	%	Total No on Treatment - June 2007	Target No on Treatment - March 2008	Target No on Treatment - March 2009	Target No on Treatment - March 2010
Princess Marina Hospital	Adult 1st Line	84.31%	13,980	16,603	19,224	21,846
	Adult 2nd Line	8.53%	1,414	1,680	1,945	2,210
	Pediatric 1st Line	5.72%	948	1,126	1,304	1,482
	Pediatric 2nd Line	1.44%	239	283	328	373
Total		100.00%	16,581	19,692	22,802	25,911
Nyangabwe Hospital	Adult 1st Line	80.82%	8,586	10,197	11,807	13,417
	Adult 2nd Line	7.04%	748	889	1,029	1,169
	Pediatric 1st Line	11.18%	1,187	1,410	1,633	1,855
	Pediatric 2nd Line	0.96%	102	121	140	159
Total		100.00%	10,623	12,616	14,608	16,601
Other ART Sites	Adult 1st Line	90.22%	47,623	56,560	65,490	74,421
	Adult 2nd Line	1.49%	786	933	1,080	1,228
	Pediatric 1st Line	8.02%	4,231	5,025	5,818	6,612
	Pediatric 2nd Line	0.28%	146	173	201	228
Total		100.00%	52,786	62,691	72,590	82,488
OVERALL TOTAL			79,990	95,000	110,000	125,000

Adult ART

1. Total number of adults on treatment is given by the MASA report of 2007 as 73,137. The regimen distribution and breakdown for adults was obtained from aggregation and analysis of site data and is presented in Table 4 to Table 6.

Table 4: Regimen Breakdown by Site: Adults

Site	Princess Marina Hospital		Nyangabwe Hospital		ART Sites		TOTAL	
	Number	%	Number	%	Number	%	Number	%
Adult 1st Line	13,980	90.81%	8,586	91.98%	47,623	98.38%	70,189	95.97%
Adult 2nd Line	1,414	9.19%	748	8.02%	786	1.62%	2,948	4.03%
Total	15,394	100.00%	9,334	100.00%	48,409	100.00%	73,137	100.00%

Source: MASA ART Site Data

Table 5: Derived Distribution of Patients on Adult 1st Line Regimens

Regimen	Princess Marina (Gaborone)		Nyangabwe (Francistown)		Other ART Sites		Total	
	No	%	No	%	No	%	No	%
AZT/3TC/EFV	2,247	44.75%	1,236	51.29%	8,308	47.75%	11,791	47.50%
AZT/3TC/NVP	2,111	42.04%	737	30.58%	6,627	38.09%	9,475	38.20%
D4T/3TC/EFV	230	4.58%	241	10.00%	1,416	8.14%	1,887	7.60%
D4T/3TC/NVP	316	6.29%	196	8.13%	1,036	5.95%	1,548	6.20%
DDI/EFV/3TC	10	0.20%	0	0.00%	12	0.07%	22	0.10%
3TC/NVP/TDF	55	1.10%	0	0.00%	0	0.00%	55	0.20%
EFV600/3TC/TDF	52	1.04%	0	0.00%	0	0.00%	52	0.20%
Totals	5,021	100.00%	2,410	100.00%	17,399	100.00%	24,830	100.00%

Source: MASA ART Site Data

Table 6: Derived Distribution of Patients on Adult 2nd Line Regimens

Regimen	Princess Marina (Gaborone)		Nyangabwe (Francistown)		Other ART Sites		Total	
	No	%	No	%	No	%	No	%
3TC/DDI/LPV-r	0	0.00%	22	10.48%	0	0.00%	22	2.20%
ABC/3TC/LPV-r	0	0.00%	12	5.71%	0	0.00%	12	1.20%
ABC/DDI/LPVr	22	4.33%	0	0.00%	12	4.18%	34	3.40%
ABC/TDF/LPVr	45	8.86%	0	0.00%	0	0.00%	45	4.50%
AZT/3TC/LPV-r	110	21.65%	35	16.67%	45	15.68%	190	18.90%
AZT/DDI/LPVr	11	2.17%	0	0.00%	11	3.83%	22	2.20%
D4T/3TC/LPV-r	10	1.97%	13	6.19%	5	1.74%	28	2.80%
D4T/DDI/LPV-r	163	32.09%	128	60.95%	203	70.73%	494	49.20%
DDI/LPV-r/TDF	40	7.87%	0	0.00%	0	0.00%	40	4.00%
TDF/3TC/LPV-r	107	21.06%	0	0.00%	11	3.83%	118	11.70%
Totals	508	100.0%	210	100.0%	287	100%	1,005	100.0%

Source: MASA ART Site Data

2. All adults on Stavudine will take the 30mg tablet. This is not recognized by the current treatment guideline however, information obtained from ART program personnel on current practices indicates this trend in accordance with WHO guidelines.
3. All patients on Didanosine will take enteric coated tablets
4. 20 percent of adults weigh >60kg and 80 percent weigh <60kg.

Source: Princess Marina Hospital ART Pharmacy

5. Five percent overage added for cases of inappropriate prescription, regimens not covered in the quantification as a result of lack of data and losses from expiration and misappropriation and to account for usage on PMTCT and PEP

Pediatric ART

1. Total number of pediatrics on treatment is given by the MASA report of June 2007 as 6,853. The regimen distribution for pediatrics was obtained from aggregation and analysis of site data and is presented in Table 7 below.

Table 7: Regimen Breakdown by Site: Pediatrics

Site	Princess Marina Hospital		Nyangabwe Hospital		Other ART Sites		TOTAL	
	Number	%	Number	%	Number	%	Number	%
Pediatric 1st Line	948	79.90%	1,187	92.11%	4,231	96.67%	6,367	92.90%
Pediatric 2nd Line	239	20.10%	102	7.89%	146	3.33%	486	7.10%
Total	1,187	100.00%	1,289	100.00%	4,377	100.00%	6,853	100.00%

Source: MASA ART Site Data

2. Regimen breakdown as derived from the site data is as follows:

Table 8: Derived Distribution of Patients on Pediatric 1st Line Regimens

Regimen	Princess Marina (Gaborone)		Nyangabwe (Francistown)		Other ART Sites		Total	
	No	%	No	%	No	%	No	%
AZT/3TC/EFV	93	28.53%	286	58.37%	0	0.00%	379	31.00%
AZT/3TC/NVP	141	43.25%	36	7.35%	0	0.00%	177	14.50%
AZT/3TC/NVPSOL	42	12.88%	54	11.02%	83	20.44%	179	14.60%
D4T 15/3TC/NVP	8	2.45%	8	1.63%	0	0.00%	16	1.30%
D4T 20/3TC/NVP	20	6.14%	17	3.47%	0	0.00%	37	3.00%
D4T 30/3TC/EFV	7	2.15%	12	2.45%	0	0.00%	19	1.60%
D4T 20/3TC/EFV	5	1.53%	22	4.49%	0	0.00%	27	2.20%
D4T/3TC/NVPSOL	9	2.76%	0	0.00%	41	10.10%	50	4.10%
AZT/3TC/SOL/EFV	1	0.31%	19	3.88%	270	66.50%	290	23.70%
D4T/3TC/SOL/EFV	0	0.00%	0	0.00%	12	2.96%	12	1.00%
D4T15/3TC/NVPSOL	0	0.00%	31	6.33%	0	0.00%	31	2.50%
D4T15/3TC/EFV	0	0.00%	5	1.02%	0	0.00%	5	0.40%
Totals	326	100.0%	490	100.0%	406	100.0%	1,222	100.0%

Source: MASA ART Site Data

Table 9: Distribution of Patients on Pediatric 2nd Line Regimens

Regimen	Princess Marina (Gaborone)		Nyangabwe (Francistown)		Other ARV Sites		Total	
	No	%	No	%	No	%	No	%
AZT/3TC/LPV-r	12	14.63%	0	0.00%	0	0.00%	12	8.70%
AZT100/ABC/LPV-r	7	8.54%	0	0.00%	0	0.00%	7	5.10%
AZT100/DDI100/LPV-r	7	8.54%	0	0.00%	0	0.00%	7	5.10%
D4T 15/3TC/LPV-r	0	0.00%	0	0.00%	0	0.00%	0	0.00%
D4T 15/3TC/LPV-rsol	11	13.42%	0	0.00%	0	0.00%	11	8.00%
D4T 15/DDI/LPV-r	7	8.54%	6	14.29%	0	0.00%	13	9.40%
D4T 20/ABC/LPV-r	9	10.98%	0	0.00%	0	0.00%	9	6.50%
D4T 20/DDI/LPV-r	11	13.42%	18	42.86%	0	0.00%	29	21.00%
D4T 30/ABC/LPV-r	8	9.76%	0	0.00%	0	0.00%	8	5.80%
D4T 30/DDI/LPV-r	10	12.20%	18	42.86%	0	0.00%	28	20.30%
D4T/DDI/LPV-rSOL	0	0.00%	0	0.00%	9	64.29%	9	6.50%
D4T/3TC/LPV-rSOL	0	0.00%	0	0.00%	5	35.71%	5	3.60%
Totals	82	100.0%	42	100.0%	14	100.0%	138	100.0%

Source: MASA ART Site Data

3. 7% overage added to liquid formulations and 5% to solid dosage for cases of inappropriate prescription, regimens not covered in the quantification as a result of lack of data and losses from expiration and misappropriation and to account for usage on PMTCT and PEP
4. The dosing of following ARVs will be as indicated –
 - Zidovudine
 - 30% will take 200mg twice daily
 - 60% will take 150mg twice daily
 - 10% will take 100mg twice daily
 - All pediatrics on solution will take 100mg daily
 - Lamivudine
 - Pediatrics on solution take 50mg twice daily
 - The rest take 75mg twice daily

- Efavirenz
 - 15% will take 250mg daily
 - 50% will take 300mg daily
 - 15% will take 350mg daily
 - 20% will take 400mg daily
 - All pediatrics on Stavudine 30mg will take EFV 400mg daily
- Nevirapine
 - All pediatrics on solution will take 100mg twice daily
 - 75% of pediatrics on tablet will take 100mg twice daily
 - 25% of pediatrics on tablets will take 200mg twice daily
- Lopinavir/Ritonavir
 - 75% of pediatrics on tablet will take 400/100mg twice daily
 - 25% of pediatrics on tablets will take 200/50mg twice daily
 - All pediatrics on solution will take 200mg/50mg Lopinavir/Ritonavir twice daily
- Didanosine
 - 60% of pediatrics will take 100mg tablet twice daily
 - 30% of pediatrics will take 125mg tablet twice daily
 - All pediatrics on the suspension will take 7.5ml twice daily

Quantification Results

Table 10 provides a summary of the total ARV requirements by value based on the above assumptions for the current guidelines for the period June 2007 to March 2010, broken down by the various classes. Detailed breakdown of the requirements is presented in Table 11. The valuation of the requirement is done using CMS prices and SCMS prices for comparison.

Table 10: Summary of Value of ARV Requirements – July 2007 to March 2010

Regimen	CMS Prices	SCMS Prices
Adult First Line	\$123,970,816	\$55,659,270
Adult Second Line	\$8,159,266	\$6,824,760
Pediatric First Line	\$17,010,762	\$9,298,002
Pediatric Second Line	\$1,309,965	\$994,190
Grand Total	\$150,450,810	\$72,776,222

Table 11: Total ARV Requirements – July 2007 to March 2010

Product	Units	Pack Size	Pack Price	Packs			Value			TOTAL
				Jul 07 to Mar 08	Apr 08 to Mar 09	Apr 09 to Mar 10	Jul 07 to Mar 08	Apr 08 to Mar 09	Apr 09 to Mar 10	
Abacavir [Ziagen] 20MG/ml OSOL (PO)	ml	240	\$ 31.32	252	394	455	\$7,893	\$12,340	\$14,251	\$34,483
Abacavir 300MG/tab TAB (PO)	tab	60	\$ 72.90	3,472	5,406	6,200	\$253,109	\$394,097	\$451,980	\$1,099,186
Didanosine [Videx] 10MG/ml POSOL (PO)	ml	200	\$ 12.59	3,032	4,670	5,273	\$38,173	\$58,795	\$66,387	\$163,355
Didanosine [Videx] 50MG/tab TAB (PO)	tab	60	\$ 14.36	3,922	6,174	6,261	\$56,331	\$88,676	\$89,926	\$234,933
Didanosine 100MG/tab TAB (PO)	tab	60	\$ 15.22	769	1,212	1,190	\$11,703	\$18,445	\$18,111	\$48,259
Didanosine 25MG/tab TAB (PO)	tab	60	\$ 14.27	392	618	610	\$5,595	\$8,821	\$8,706	\$23,122
Didanosine EC [Videx EC] 400MG/cap CAP (PO)	cap	60	\$ 23.67	1,807	2,811	3,220	\$42,772	\$66,536	\$76,217	\$185,525
Didanosine EC 250MG/cap CBLIS (PO)	cap	30	\$ 22.50	15,627	24,314	27,851	\$351,608	\$547,065	\$626,648	\$1,525,320
Efavirenz [Stocrin/Sustiva] 50MG/cap CAP (PO)	cap	30	\$ 3.47	17,678	27,579	31,662	\$61,343	\$95,699	\$109,867	\$266,909
Efavirenz 200MG/cap CAP (PO)	cap	90	\$ 16.00	15,303	23,835	27,319	\$244,848	\$381,360	\$437,104	\$1,063,312
Efavirenz 600MG/tab TAB (PO)	tab	30	\$ 12.42	412,113	641,482	734,730	\$5,118,443	\$7,967,206	\$9,125,347	\$22,210,997
Lamivudine 10MG/ml OSOL (PO)	ml	240	\$ 6.73	100,718	156,762	179,550	\$677,832	\$1,055,008	\$1,208,372	\$2,941,212
Lamivudine 150MG/tab TAB (PO)	tab	60	\$ 5.70	129,383	201,424	230,753	\$737,483	\$1,148,117	\$1,315,292	\$3,200,892
Lamivudine-Zidovudine 150+300MG/tab TAB (PO)	tab	60	\$ 18.50	635,037	988,476	1,132,160	\$11,748,185	\$18,286,806	\$20,944,960	\$50,979,951
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab TAB (PO)	tab	180	\$ 41.10	22,093	34,397	39,190	\$908,022	\$1,413,717	\$1,610,709	\$3,932,448
Lopinavir-Ritonavir [Kaletra] 80+20MG/ml OSOL (PO)	ml	300	\$ 41.10	1,151	1,778	2,016	\$47,306	\$73,076	\$82,858	\$203,240
Nevirapine [Viramune] 10MG/ml OSUS (PO)	ml	240	\$ 26.28	52,598	81,896	93,835	\$1,382,465	\$2,152,522	\$2,466,322	\$6,001,308
Nevirapine 200mg [Viramune], tablets, 60 tablets	tab	60	\$ 31.54	334,705	521,000	596,744	\$10,556,703	\$16,432,507	\$18,821,497	\$45,810,706
Ritonavir 100MG/cap CAP (PO)	cap	84	\$ 9.62	692	1,078	1,236	\$6,657	\$10,370	\$11,890	\$28,917
Saquinavir [Invirase] 200MG/cap CAP (PO)	cap	270	\$ 76.59	473	736	844	\$36,226	\$56,368	\$64,639	\$157,233
Stavudine [Zerit] 15MG/cap CAP (PO)	cap	60	\$ 2.84	2,084	3,258	3,681	\$5,919	\$9,253	\$10,454	\$25,625
Stavudine 1MG/ml POSOL (PO)	ml	200	\$ 1.70	23,426	36,384	41,553	\$39,934	\$62,023	\$70,835	\$172,791
Stavudine 20MG/cap CAP (PO)	cap	60	\$ 5.70	2,848	4,457	4,920	\$16,233	\$25,404	\$28,043	\$69,680
Stavudine 30MG/cap CAP (PO)	cap	60	\$ 5.70	120,866	188,147	215,311	\$688,910	\$1,072,398	\$1,227,227	\$2,988,535
Tenofovir disoproxil fumarate 300MG/tab TAB (PO)	tab	30	\$ 18.75	9,573	14,889	17,052	\$179,494	\$279,169	\$319,725	\$778,388
Zidovudine [Retrovir] 10MG/ml OSOL (PO)	ml	200	\$ 7.10	153,669	239,191	273,982	\$1,091,050	\$1,698,256	\$1,945,272	\$4,734,578
Zidovudine [Retrovir] 300MG/tab TAB (PO)	tab	60	\$ 17.40	14,527	22,634	25,958	\$252,770	\$393,832	\$451,669	\$1,098,271
Zidovudine 100MG/cap CAP (PO)	cap	100	\$ 15.77	6,873	10,723	12,311	\$108,387	\$169,102	\$194,144	\$471,633
TOTAL							\$34,675,392	\$53,976,968	\$61,798,450	\$150,450,810

Table 12 provides further detailed breakdown of the requirements by site, regimen and age grouping.

Table 12: Total Requirements by Regimen and Site

Regimen	Hospital	CMS	SCMS
Adult First Line	Nyangambwe Hospital	\$14,598,046	\$6,910,697
	Other ART Sites	\$83,874,064	\$37,732,177
	Princess Marina Hospital	\$25,498,707	\$11,016,395
Adult First Line Total		\$123,970,816	\$55,659,270
Adult Second Line	Nyangambwe Hospital	\$1,973,114	\$1,657,990
	Other ART Sites	\$2,007,897	\$1,714,312
	Princess Marina Hospital	\$4,178,255	\$3,452,458
Adult Second Line Total		\$8,159,266	\$6,824,760
Pediatric First Line	Nyangambwe Hospital	\$2,435,084	\$1,307,736
	Other ART Sites	\$12,677,207	\$7,128,726
	Princess Marina Hospital	\$1,898,471	\$861,540
Pediatric First Line Total		\$17,010,762	\$9,298,002
Pediatric Second Line	Nyangambwe Hospital	\$255,303	\$182,569
	Other ART Sites	\$396,024	\$366,999
	Princess Marina Hospital	\$658,638	\$444,623
Pediatric Second Line Total		\$1,309,965	\$994,190
Grand Total		\$150,450,810	\$72,776,222

Supply Plan

The supply plan for ARVs required for the period July 2007 to December 2008 was generated using the PipeLine® tool. The inventory position as at June 30, 2007 was used taking into consideration all known sources of supply. Stocks on hand at the CMS were considered however, stocks on hand at the ART sites were not input into the calculations. Inventory parameters used for the supply plan were:

- Program Maximum Stock: 12 months
- Program Minimum Stock: 5 months
- Program Desired Stock: 10 months
- Central Level Maximum Stock: 7 months
- Central Level Minimum Stock: 4 months

The following lead time parameters were assumed:

- Plan to order 0.5 Months
- Order to ship 3 Months
- Ship to receive 0.5 Months
- A freight estimate of 12 percent was applied.

Based on the above parameters a shipment schedule based on quarterly shipments was planned for receipts in February, May, August and November 2008. The shipment schedule presented on page 19 and stock status report is presented in Appendix 4.

At the procurement stage the supply plan should be updated with current stock on hand levels and receipts and adjustments made for other donation sources before arriving at procurement quantities.

The supply plan should ideally be updated on a monthly basis to accommodate changes in pipeline status.

Shipment Summary by Supplier

Report Period: Jan 2007 - Dec 2008

Category: ALL
 Supplier: AUROBIND00, DONATION00, GOB00
 Status: Planned

Supplier

Supplier Type	Product	Receipt Date	Quantity	Status	ID	-----Costs-----		
						Product	Freight	Total
GOB/CMS								
Antiretrovirals								
	Abacavir 20mg/ml [Ziagen] 240 ml							
		29-Feb-08	120	Planned	45	3,758	451	4,209
		31-May-08	96	Planned	61	3,007	361	3,368
		31-Aug-08	108	Planned	77	3,383	406	3,788
		30-Nov-08	96	Planned	93	3,007	361	3,368
	Abacavir 300mg 60 Tabs							
		29-Feb-08	4,230	Planned	53	308,367	37,004	345,371
		31-May-08	1,350	Planned	69	98,415	11,810	110,225
		31-Aug-08	1,350	Planned	85	98,415	11,810	110,225
		30-Nov-08	1,530	Planned	101	111,537	13,384	124,921
	Didanosine 2g/237ml [Videx] reconstitute 200 ml							
		29-Feb-08	5,888	Planned	46	74,130	8,896	83,026
		31-May-08	1,152	Planned	62	14,504	1,740	16,244
		31-Aug-08	1,184	Planned	78	14,907	1,789	16,695
		30-Nov-08	1,216	Planned	94	15,309	1,837	17,147
	Didanosine 50mg [Videx] 60 Tabs							
		29-Feb-08	1,440	Planned	47	20,678	2,481	23,160
		31-May-08	1,600	Planned	63	22,976	2,757	25,733
		31-Aug-08	1,600	Planned	79	22,976	2,757	25,733
		30-Nov-08	1,680	Planned	95	24,125	2,895	27,020
	Didanosine EC 400mg [Videx EC] 30 Caps							
		29-Feb-08	5,650	Planned	48	133,736	16,048	149,784
		31-May-08	1,400	Planned	64	33,138	3,977	37,115
		31-Aug-08	1,450	Planned	80	34,322	4,119	38,440
		30-Nov-08	1,500	Planned	96	35,505	4,261	39,766
	Efavirenz 600mg 30 Tabs							
		29-Feb-08	510,804	Planned	52	6,344,186	761,302	7,105,488
		31-May-08	161,700	Planned	68	2,008,314	240,998	2,249,312
		31-Aug-08	166,656	Planned	84	2,069,868	248,384	2,318,252
		30-Nov-08	172,116	Planned	100	2,137,681	256,522	2,394,202
	Lamivudine 10mg/ml 240 ml							
		29-Feb-08	115,500	Planned	57	777,315	93,278	870,593
		31-May-08	38,815	Planned	73	261,225	31,347	292,572
		31-Aug-08	39,935	Planned	89	268,763	32,252	301,014
		30-Nov-08	41,300	Planned	105	277,949	33,354	311,303
	Lamivudine 150mg 60 Tabs							
		29-Feb-08	122,490	Planned	59	698,193	83,783	781,976
		31-May-08	50,760	Planned	75	289,332	34,720	324,052
		31-Aug-08	52,290	Planned	91	298,053	35,766	333,819
		30-Nov-08	54,090	Planned	107	308,313	36,998	345,311
	Lamivudine/Zidovudine 150/300mg 60 Tabs							
		29-Feb-08	575,184	Planned	55	10,640,904	1,276,908	11,917,812
		31-May-08	249,264	Planned	71	4,611,384	553,366	5,164,750
		31-Aug-08	256,704	Planned	87	4,749,024	569,883	5,318,907
		30-Nov-08	265,296	Planned	103	4,907,976	588,957	5,496,933

Shipment Summary by Supplier

Report Period: Jan 2007 - Dec 2008

Supplier

Type

Product	Receipt Date	Quantity	Status	ID	-----Costs-----			
					Product	Freight	Total	
Lopinavir/Ritonavir 200/50mg [Aluvia] 120 Tabs								
	29-Feb-08	54,880	Planned	49	2,255,568	270,668	2,526,236	
	31-May-08	13,000	Planned	65	534,300	64,116	598,416	
	31-Aug-08	13,400	Planned	81	550,740	66,089	616,829	
	30-Nov-08	13,880	Planned	97	570,468	68,456	638,924	
Nevirapine 10mg/ml [Viramune] 240 ml								
	29-Feb-08	19,906	Planned	50	523,130	62,776	585,905	
	31-May-08	20,265	Planned	66	532,564	63,908	596,472	
	31-Aug-08	20,883	Planned	82	548,805	65,857	614,662	
	30-Nov-08	21,570	Planned	98	566,860	68,023	634,883	
Nevirapine 200mg 60 Tabs								
	29-Feb-08	218,625	Planned	54	6,895,433	827,452	7,722,884	
	31-May-08	131,400	Planned	70	4,144,356	497,323	4,641,679	
	31-Aug-08	135,300	Planned	86	4,267,362	512,083	4,779,445	
	30-Nov-08	139,875	Planned	102	4,411,658	529,399	4,941,056	
Stavudine 1mg/ml 200 ml								
	29-Feb-08	27,950	Planned	56	47,515	5,702	53,217	
	31-May-08	9,000	Planned	72	15,300	1,836	17,136	
	31-Aug-08	9,250	Planned	88	15,725	1,887	17,612	
	30-Nov-08	9,550	Planned	104	16,235	1,948	18,183	
Stavudine 30mg 60 Caps								
	29-Feb-08	136,710	Planned	58	779,247	93,510	872,757	
	31-May-08	47,430	Planned	74	270,351	32,442	302,793	
	31-Aug-08	48,870	Planned	90	278,559	33,427	311,986	
	30-Nov-08	50,580	Planned	106	288,306	34,597	322,903	
Tenofovir disoproxil fumarate 300mg 30 Tabs								
	29-Feb-08	14,865	Planned	60	278,719	33,446	312,165	
	31-May-08	3,749	Planned	76	70,294	8,435	78,729	
	31-Aug-08	3,868	Planned	92	72,525	8,703	81,228	
	30-Nov-08	3,996	Planned	108	74,925	8,991	83,916	
Zidovudine 10mg/ml [Retrovir] 200 ml								
	29-Feb-08	259,356	Planned	51	1,841,428	220,971	2,062,399	
	31-May-08	59,184	Planned	67	420,206	50,425	470,631	
	31-Aug-08	60,960	Planned	83	432,816	51,938	484,754	
	30-Nov-08	63,000	Planned	99	447,300	53,676	500,976	
Antiretrovirals Total						72,875,365	8,745,044	81,620,408
GOB/CMS Total						72,875,365	8,745,044	81,620,408
Grand Total						72,875,365	8,745,044	81,620,408


Findings and Recommendations

Findings

The following provides a summary of the general findings during the quantification exercise –

- a) Table 10 provides a summary of the value of ARVs required for the period July 2007 to March 2010. Based on the MASA Scale up projections a total of \$150M is required for the program. Using generic alternatives at SCMS prices the total requirement reduces to about \$73M which is less than half (48%) of the CMS cost. This implies that introducing more generics into the system will have a major impact on the resources required to be allocated to HIV/AIDS.
- b) Figure 2 shows the consumption of selected pediatric formulations in the CMS between January and 2007. It will be noted that irrespective of the scale up of patient numbers, the consumption of the liquid formulations are either falling or remains steady over the review period. The reasons for this behavior could not be ascertained given the time available, however, it appears that there is a higher tendency to dispense tablets in place of liquids even to pediatrics to avoid the cumbersome handling of numerous bottles. It was also noted from CMS, Nyangabgwe and Princess Marina Pharmacy Staff that the Baylor Pediatric Centre of Excellence Project is promoting the use of tablets and capsules for pediatrics by care givers instead of syrups resulting in the drastic drop in the syrup consumption. This trend needs to be further studied and the projections for liquid formulations adjusted accordingly.

Figure 2: CMS Consumption of Pediatric ARVs



- c) Generally, data required for the quantification of ARVs were not available in the form suitable for morbidity based quantification. The information system currently in use is not designed to collect and process the required data elements such as regimen breakdown, switch rates, numbers of patients on treatment stratified by age, weight etc. required for morbidity based quantification, thus further analysis of the data was required. However, adequate data and assumptions could be derived from the available data to conduct a preliminary forecast
- d) There is general weakness in the systems for collection, management and publication of logistics and morbidity data required for quantification and supply planning
- e) The ART treatment guidelines and protocols are under review and implementation timeframes are unclear
- f) There is no central focus on logistics management and supply planning for ARVs and other HIV/AIDS related commodities

Recommendations

The following general recommendations are made:

- a. Consider switching to generic alternatives for ARVs where available
- b. Investigate the use of liquid formulations and the rate of use of solid dosage forms in lieu of liquids in pediatrics
- c. Put systems in place in all ART sites and the headquarters to collect data for quantification
- d. Set up a central HIV/AIDS-related Commodity Tracking System, capable of the collection, processing and presentation of data required for pipeline monitoring, forecasting, quantification and supply planning for HIV/AIDS commodities
- e. Set up a centralized system for quarterly updates of the 24-month quantification and supply plan based on updated data and actual progress of program implementation
- f. Set up a national forum composed of partners and stakeholders, for regular discussions of the HIV/AIDS commodity supply system to ensure commodity security
- g. Update forecast in line with changes in ART regimens, medicines prices and exchange rates
- h. Develop a data collection mechanism to track information on:
 - i. PEP
 - ii. Adult and pediatric second line regimens breakdowns
 - iii. Pediatric weight distribution
 - iv. Rate of migration from first to second line regimen
 - v. Proportion of pediatrics on solid and liquid dosage forms
 - vi. Stock on hand and pipeline information on all commodities

- i. Conduct an ART regimen audit to establish actual regimens in use and regimen breakdowns
- j. Develop a comprehensive plan and timeline, incorporating logistics considerations for the implementation of the new ART guidelines

Appendix 1: CMS and SCMS Prices

Medicines

Data Set: Botswana Quantification September 2007

Price Type: Central Medical Stores

Currency: US

Code	Product	Additional Info	Therapeutic Class	VEN	User EML	Purchase Pack	Unit	Unit Price	Source
102002	Abacavir [Ziagen] 20MG/ml	Ziagen		V		BOTT	ml	0.1305	CMS
102159	Abacavir 300MG/tab			V		BOTT	tab	1.2150	CMS
102010	Didanosine [Videx] 100MG/tab	Videx		V		BOTT	tab	0.2537	CMS
102007	Didanosine [Videx] 10MG/ml	Videx		V		BOTT	ml	0.0630	SCMS
102011	Didanosine [Videx] 150MG/tab	Videx		V		BOTT	tab	0.3083	SCMS
102012	Didanosine [Videx] 200MG/tab	Videx		V		BOTT	tab	0.4250	SCMS
102013	Didanosine [Videx] 400MG/tab	Videx		V		BOTT	tab	0.7890	SCMS
102009	Didanosine [Videx] 50MG/tab	Videx		V		BOTT	tab	0.2394	CMS
102161	Didanosine 100MG/tab			V		BOTT	tab	0.2537	CMS
102691	Didanosine 25MG/tab			V		BOTT	tab	0.2379	CMS
102017	Didanosine EC [Videx EC] 400MG/cap	Videx EC		V		BOTT	cap	0.7890	SCMS
102696	Didanosine EC 250MG/cap			V		BOTT	cap	0.7500	Idris
102019	Efavirenz [Stocrin/Sustiva] 50MG/cap	Stocrin/Sustiva		V		BOTT	cap	0.1157	
102592	Efavirenz 200MG/cap			V		BOTT	cap	0.1778	SCMS
102158	Efavirenz 600MG/tab			V		BOTT	tab	0.4140	SCMS
102191	Lamivudine 10MG/ml			V		BOTT	ml	0.0280	CMS
102193	Lamivudine 150MG/tab			V		BOTT	tab	0.0950	CMS
102162	Lamivudine-Zidovudine 150+300MG/tab			V		BOTT	tab	0.3083	CMS
102033	Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	Aluvia		V		BOTT	tab	0.3425	CMS
102430	Lopinavir-Ritonavir [Kaletra] 80+20MG/ml	Kaletra		V		BOTT	ml	0.1370	CMS
102038	Nevirapine [Viramune] 10MG/ml	Viramune		V		BOTT	ml	0.1095	CMS
102160	Nevirapine 200MG/tab			V		BOTT	tab	0.5257	CMS
102724	Ritonavir 100MG/cap			V		BOTT	cap	0.1145	CMS
102041	Saquinavir [Invirase] 200MG/cap	Invirase		V		BOTT	cap	0.2837	CMS
102042	Stavudine [Zerit] 15MG/cap	Zerit		V		BOTT	cap	0.0473	CMS
102046	Stavudine [Zerit] 1MG/ml	Zerit		V		BOTT	ml	0.0085	CMS
102163	Stavudine 1MG/ml			V		BOTT	ml	0.0085	CMS
102189	Stavudine 20MG/cap			V		BOTT	cap	0.0950	CMS
102192	Stavudine 30MG/cap			V		BOTT	cap	0.0950	CMS
102728	Tenofovir disoproxil fumarate 300MG/tab			V		BOTT	tab	0.6250	CMS
102052	Zidovudine [Retrovir] 10MG/ml	Retrovir		V		BOTT	ml	0.0296	CMS
102049	Zidovudine [Retrovir] 300MG/tab	Retrovir		V		BOTT	tab	0.2900	CMS
102164	Zidovudine 100MG/cap			V		BOTT	cap	0.1577	CMS

Thursday, January 10, 2008

Page 1 of 1

Medicines

Data Set: Botswana Quantification September 2007

Price Type: SCMS

Currency: US

Code	Product	Additional Info	Therapeutic Class	VEN	User EML	Purchase Pack	Unit	Unit Price	Source
102002	Abacavir [Ziagen] 20MG/ml	Ziagen		V		BOTT	ml	0.1042	SCMS
102159	Abacavir 300MG/tab			V		BOTT	tab	0.4588	SCMS
102010	Didanosine [Videx] 100MG/tab	Videx		V		BOTT	tab	0.2125	SCMS
102007	Didanosine [Videx] 10MG/ml	Videx		V		BOTT	ml	0.0630	SCMS
102011	Didanosine [Videx] 150MG/tab	Videx		V		BOTT	tab	0.3083	SCMS
102012	Didanosine [Videx] 200MG/tab	Videx		V		BOTT	tab	0.4250	SCMS
102013	Didanosine [Videx] 400MG/tab	Videx		V		BOTT	tab	0.7890	SCMS
102009	Didanosine [Videx] 50MG/tab	Videx		V		BOTT	tab	0.1583	SCMS
102161	Didanosine 100MG/tab			V		BOTT	tab	0.1292	SCMS
102691	Didanosine 25MG/tab			V		BOTT	tab	0.2379	SCMS
102017	Didanosine EC [Videx EC] 400MG/cap	Videx EC		V		BOTT	cap	0.7890	SCMS
102696	Didanosine EC 250MG/cap			V		BOTT	cap	0.6113	SCMS
102019	Efavirenz [Stocrin/Sustiva] 50MG/cap	Stocrin/Sustiva		V		BOTT	cap	0.1157	SCMS
102592	Efavirenz 200MG/cap			V		BOTT	cap	0.1778	SCMS
102158	Efavirenz 600MG/tab			V		BOTT	tab	0.4140	SCMS
102191	Lamivudine 10MG/ml			V		BOTT	ml	0.0082	SCMS
102193	Lamivudine 150MG/tab			V		BOTT	tab	0.0507	SCMS
102162	Lamivudine-Zidovudine 150+300MG/tab			V		BOTT	tab	0.1583	SCMS
102033	Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	Aluvia		V		BOTT	tab	0.3425	SCMS
102430	Lopinavir-Ritonavir [Kaletra] 80+20MG/ml	Kaletra		V		BOTT	ml	0.1370	SCMS
102038	Nevirapine [Viramune] 10MG/ml	Viramune		V		BOTT	ml	0.0521	SCMS
102160	Nevirapine 200MG/tab			V		BOTT	tab	0.0567	SCMS
102724	Ritonavir 100MG/cap			V		BOTT	cap	0.2283	SCMS
102041	Saquinavir [Invirase] 200MG/cap	Invirase		V		BOTT	cap	0.2931	SCMS
102042	Stavudine [Zerit] 15MG/cap	Zerit		V		BOTT	cap	0.0822	SCMS
102046	Stavudine [Zerit] 1MG/ml	Zerit		V		BOTT	ml	0.0075	SCMS
102163	Stavudine 1MG/ml			V		BOTT	ml	0.0070	SCMS
102189	Stavudine 20MG/cap			V		BOTT	cap	0.0292	SCMS
102192	Stavudine 30MG/cap			V		BOTT	cap	0.0253	SCMS
102728	Tenofovir disoproxil fumarate 300MG/tab			V		BOTT	tab	0.5667	SCMS
102052	Zidovudine [Retrovir] 10MG/ml	Retrovir		V		BOTT	ml	0.0355	SCMS
102049	Zidovudine [Retrovir] 300MG/tab	Retrovir		V		BOTT	tab	0.2900	SCMS
102164	Zidovudine 100MG/cap			V		BOTT	cap	0.0549	SCMS

Thursday, January 10, 2008

Page 1 of 1

Appendix 2: Pipeline Stock Status Report

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Abacavir 20mg/ml [Ziagen] 240 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			-----Consumption-----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	301	18.8		109	301
Jul-07	301				24	<input type="checkbox"/>		11.5			277
Aug-07	277				25	<input type="checkbox"/>	58	12.4		10	310
Sep-07	310				25	<input type="checkbox"/>		11.4			285
Oct-07	285				26	<input type="checkbox"/>		10.0	1		259
Nov-07	259	10	Ordered	GOB/CMS	26	<input type="checkbox"/>		9.3	17		243
Dec-07	243				27	<input type="checkbox"/>		8.0	54		216
Jan-08	216				27	<input type="checkbox"/>		7.0	81		189
Feb-08	189	120	Planned	GOB/CMS	28	<input type="checkbox"/>		10.0			281
Mar-08	281				28	<input type="checkbox"/>		9.0	27		253
Apr-08	253				28	<input type="checkbox"/>		8.0	55		225
May-08	225	96	Planned	GOB/CMS	29	<input type="checkbox"/>		10.1			292
Jun-08	292				29	<input type="checkbox"/>		9.1	27		263
Jul-08	263				30	<input type="checkbox"/>		7.8	67		233
Aug-08	233	108	Planned	GOB/CMS	30	<input type="checkbox"/>		10.4			311
Sep-08	311				30	<input type="checkbox"/>		9.4	19		281
Oct-08	281				31	<input type="checkbox"/>		8.1	60		250
Nov-08	250	96	Planned	GOB/CMS	31	<input type="checkbox"/>		10.2			315
Dec-08	315				32	<input type="checkbox"/>		8.8	37		283

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Abacavir 300mg 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	1,921	8.4	369		1,921
Jul-07	1,921				340	<input type="checkbox"/>		4.6	1,889	-154	1,581
Aug-07	1,581				347	<input type="checkbox"/>	763	5.7	1,533		1,997
Sep-07	1,997				354	<input type="checkbox"/>		4.6	1,957	-157	1,643
Oct-07	1,643				360	<input type="checkbox"/>		3.5	2,387	-552	1,283
Nov-07	1,283	15	Ordered	GOB/CMS	367	<input type="checkbox"/>		2.5	2,809	-939	931
Dec-07	931				374	<input type="checkbox"/>		1.5	3,253	-1,348	557
Jan-08	557				381	<input type="checkbox"/>		.5	3,704	-1,764	176
Feb-08	176	4,230	Planned	GOB/CMS	388	<input type="checkbox"/>		10.2			4,018
Mar-08	4,018				395	<input type="checkbox"/>		9.1	377		3,623
Apr-08	3,623				400	<input type="checkbox"/>		8.0	827		3,223
May-08	3,223	1,350	Planned	GOB/CMS	405	<input type="checkbox"/>		10.2			4,168
Jun-08	4,168				411	<input type="checkbox"/>		9.0	403		3,757
Jul-08	3,757				416	<input type="checkbox"/>		7.9	869		3,341
Aug-08	3,341	1,350	Planned	GOB/CMS	421	<input type="checkbox"/>		10.0			4,270
Sep-08	4,270				426	<input type="checkbox"/>		8.9	466		3,844
Oct-08	3,844				432	<input type="checkbox"/>		7.8	958		3,412
Nov-08	3,412	1,530	Planned	GOB/CMS	437	<input type="checkbox"/>		10.2			4,505
Dec-08	4,505				442	<input type="checkbox"/>		9.1	407		4,063

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Didanosine 100mg 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	6,082	121.6		5,482	6,082
Jul-07	6,082				75	<input type="checkbox"/>		79.0		5,095	6,007
Aug-07	6,007				77	<input type="checkbox"/>	6,617	160.9		11,611	12,547
Sep-07	12,547				78	<input type="checkbox"/>		157.8		11,521	12,469
Oct-07	12,469				80	<input type="checkbox"/>		153.0		11,417	12,389
Nov-07	12,389	27,769	Ordered	GOB/CMS	81	<input type="checkbox"/>		488.7		39,093	40,077
Dec-07	40,077				83	<input type="checkbox"/>		476.1		38,986	39,994
Jan-08	39,994				84	<input type="checkbox"/>		469.5		38,890	39,910
Feb-08	39,910				86	<input type="checkbox"/>		457.7		38,780	39,824
Mar-08	39,824				87	<input type="checkbox"/>		451.6		38,681	39,737
Apr-08	39,737				89	<input type="checkbox"/>		440.5		38,568	39,648
May-08	39,648				90	<input type="checkbox"/>		434.7		38,466	39,558
Jun-08	39,558				91	<input type="checkbox"/>		429.0		38,363	39,467
Jul-08	39,467				93	<input type="checkbox"/>		418.9		38,246	39,374
Aug-08	39,374				94	<input type="checkbox"/>		413.5		38,140	39,280
Sep-08	39,280				95	<input type="checkbox"/>		408.2		38,033	39,185
Oct-08	39,185				97	<input type="checkbox"/>		398.9		37,912	39,088
Nov-08	39,088				98	<input type="checkbox"/>		393.8		37,802	38,990
Dec-08	38,990				100	<input type="checkbox"/>		385.0		37,678	38,890

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Didanosine 25mg 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	160	6.4	90		160
Jul-07	160				38	<input type="checkbox"/>		3.1	268	-73	122
Aug-07	122				39	<input type="checkbox"/>	194	6.9	123		277
Sep-07	277	510	Received	GOB/CMS	40	<input type="checkbox"/>		18.7		267	747
Oct-07	747				41	<input type="checkbox"/>		17.2		214	706
Nov-07	706	1,230	Ordered	GOB/CMS	41	<input type="checkbox"/>		45.1		1,391	1,895
Dec-07	1,895				42	<input type="checkbox"/>		43.1		1,337	1,853
Jan-08	1,853				43	<input type="checkbox"/>		41.1		1,282	1,810
Feb-08	1,810				44	<input type="checkbox"/>		40.1		1,238	1,766
Mar-08	1,766				45	<input type="checkbox"/>		38.2		1,181	1,721
Apr-08	1,721				45	<input type="checkbox"/>		36.4		1,124	1,676
May-08	1,676				46	<input type="checkbox"/>		35.4		1,078	1,630
Jun-08	1,630				47	<input type="checkbox"/>		33.7		1,019	1,583
Jul-08	1,583				47	<input type="checkbox"/>		32.0		960	1,536
Aug-08	1,536				48	<input type="checkbox"/>		31.0		912	1,488
Sep-08	1,488				49	<input type="checkbox"/>		29.4		851	1,439
Oct-08	1,439				49	<input type="checkbox"/>		27.8		790	1,390
Nov-08	1,390				50	<input type="checkbox"/>		26.8		740	1,340
Dec-08	1,340				51	<input type="checkbox"/>		25.3		677	1,289

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Didanosine 2g/237ml [Videx] reconstitute 200 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			-----Consumption-----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jul-07					291	<input type="checkbox"/>		-1.0	3,261	-1,776	-291
Aug-07	-291				297	<input type="checkbox"/>		-1.9	3,618	-2,103	-588
Sep-07	-588				303	<input type="checkbox"/>		-2.9	3,981	-2,436	-891
Oct-07	-891				309	<input type="checkbox"/>		-3.8	4,350	-2,775	-1,200
Nov-07	-1,200				315	<input type="checkbox"/>		-4.7	4,725	-3,120	-1,515
Dec-07	-1,515				321	<input type="checkbox"/>		-5.6	5,096	-3,466	-1,836
Jan-08	-1,836				327	<input type="checkbox"/>		-6.5	5,483	-3,823	-2,163
Feb-08	-2,163	5,888	Planned	GOB/CMS	332	<input type="checkbox"/>		10.1			3,393
Mar-08	3,393				338	<input type="checkbox"/>		8.9	365		3,055
Apr-08	3,055				342	<input type="checkbox"/>		7.8	747		2,713
May-08	2,713	1,152	Planned	GOB/CMS	346	<input type="checkbox"/>		10.1			3,519
Jun-08	3,519				350	<input type="checkbox"/>		9.0	371		3,169
Jul-08	3,169				354	<input type="checkbox"/>		7.9	765		2,815
Aug-08	2,815	1,184	Planned	GOB/CMS	358	<input type="checkbox"/>		10.1			3,641
Sep-08	3,641				362	<input type="checkbox"/>		9.0	381		3,279
Oct-08	3,279				366	<input type="checkbox"/>		7.9	777		2,913
Nov-08	2,913	1,216	Planned	GOB/CMS	370	<input type="checkbox"/>		10.1			3,759
Dec-08	3,759				373	<input type="checkbox"/>		9.0	384		3,386

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Didanosine 50mg [Videx] 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	575	2.2	2,005	-715	575
Jul-07	575				384	<input type="checkbox"/>		.5	3,729	-1,769	191
Aug-07	191				392	<input type="checkbox"/>	561	.9	3,630	-1,635	360
Sep-07	360	520	Received	GOB/CMS	400	<input type="checkbox"/>		1.2	3,590	-1,555	480
Oct-07	480				407	<input type="checkbox"/>		.2	4,077	-2,002	73
Nov-07	73	4,648	Ordered	GOB/CMS	415	<input type="checkbox"/>		10.2			4,306
Dec-07	4,306				423	<input type="checkbox"/>		9.0	417		3,883
Jan-08	3,883				430	<input type="checkbox"/>		7.9	927		3,453
Feb-08	3,453	1,440	Planned	GOB/CMS	438	<input type="checkbox"/>		10.0			4,455
Mar-08	4,455				446	<input type="checkbox"/>		8.9	511		4,009
Apr-08	4,009				452	<input type="checkbox"/>		7.7	1,033		3,557
May-08	3,557	1,600	Planned	GOB/CMS	459	<input type="checkbox"/>		10.1			4,698
Jun-08	4,698				466	<input type="checkbox"/>		8.9	498		4,232
Jul-08	4,232				473	<input type="checkbox"/>		7.8	1,041		3,759
Aug-08	3,759	1,600	Planned	GOB/CMS	480	<input type="checkbox"/>		10.0			4,879
Sep-08	4,879				487	<input type="checkbox"/>		8.9	538		4,392
Oct-08	4,392				493	<input type="checkbox"/>		7.8	1,101		3,899
Nov-08	3,899	1,680	Planned	GOB/CMS	500	<input type="checkbox"/>		10.0			5,079
Dec-08	5,079				507	<input type="checkbox"/>		8.9	568		4,572

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Didanosine EC 250mg blister 30 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>		.0	10,290	-5,145	
Jul-07					1,529	<input type="checkbox"/>		-1.0	17,129	-9,329	-1,529
Aug-07	-1,529				1,560	<input type="checkbox"/>		-1.9	18,999	-11,044	-3,089
Sep-07	-3,089	120	Received	DONATION	1,592	<input type="checkbox"/>		-2.8	20,791	-12,676	-4,561
Oct-07	-4,561				1,623	<input type="checkbox"/>		-3.7	22,724	-14,454	-6,184
Nov-07	-6,184	81,624	Ordered	DONATION	1,654	<input type="checkbox"/>		43.8		53,566	73,786
Dec-07	73,786				1,685	<input type="checkbox"/>		42.0		51,509	72,101
Jan-08	72,101				1,716	<input type="checkbox"/>		40.3		49,421	70,385
Feb-08	70,385				1,747	<input type="checkbox"/>		38.7		47,338	68,638
Mar-08	68,638				1,778	<input type="checkbox"/>		37.1		45,248	66,860
Apr-08	66,860				1,801	<input type="checkbox"/>		35.7		43,171	65,059
May-08	65,059				1,824	<input type="checkbox"/>		34.2		41,071	63,235
Jun-08	63,235				1,848	<input type="checkbox"/>		32.8		38,935	61,387
Jul-08	61,387				1,871	<input type="checkbox"/>		31.4		36,788	59,516
Aug-08	59,516				1,895	<input type="checkbox"/>		30.0		34,605	57,621
Sep-08	57,621				1,918	<input type="checkbox"/>		28.7		32,411	55,703
Oct-08	55,703				1,941	<input type="checkbox"/>		27.4		30,194	53,762
Nov-08	53,762				1,965	<input type="checkbox"/>		26.1		27,941	51,797
Dec-08	51,797				1,988	<input type="checkbox"/>		24.8		25,677	49,809

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Didanosine EC 400mg [Videx EC] 30 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>		.0	2,380	-1,190	
Jul-07					354	<input type="checkbox"/>		-1.0	3,964	-2,159	-354
Aug-07	-354				361	<input type="checkbox"/>		-1.9	4,395	-2,555	-715
Sep-07	-715	1,399	Received	DONATION	368	<input type="checkbox"/>		.8	3,434	-1,559	316
Oct-07	316				375	<input type="checkbox"/>		-.2	3,879	-1,969	-59
Nov-07	-59	120	Ordered	DONATION	382	<input type="checkbox"/>		-.8	4,211	-2,266	-321
Dec-07	-321				389	<input type="checkbox"/>		-1.8	4,670	-2,690	-710
Jan-08	-710				397	<input type="checkbox"/>		-2.7	5,147	-3,127	-1,107
Feb-08	-1,107	5,650	Planned	GOB/CMS	404	<input type="checkbox"/>		10.1			4,139
Mar-08	4,139				411	<input type="checkbox"/>		9.0	432		3,728
Apr-08	3,728				416	<input type="checkbox"/>		7.9	898		3,312
May-08	3,312	1,400	Planned	GOB/CMS	422	<input type="checkbox"/>		10.0			4,290
Jun-08	4,290				427	<input type="checkbox"/>		8.9	457		3,863
Jul-08	3,863				433	<input type="checkbox"/>		7.8	950		3,430
Aug-08	3,430	1,450	Planned	GOB/CMS	438	<input type="checkbox"/>		10.0			4,442
Sep-08	4,442				443	<input type="checkbox"/>		8.9	481		3,999
Oct-08	3,999				449	<input type="checkbox"/>		7.8	990		3,550
Nov-08	3,550	1,500	Planned	GOB/CMS	454	<input type="checkbox"/>		10.0			4,596
Dec-08	4,596				460	<input type="checkbox"/>		8.9	514		4,136

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Efavirenz 200mg 90 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	30,985	30.7		18,889	30,985
Jul-07	30,985				1,497	<input type="checkbox"/>		19.3		11,164	29,488
Aug-07	29,488				1,527	<input type="checkbox"/>	3,394	20.1		12,659	31,355
Sep-07	31,355	10,508	Received	DONATION	1,558	<input type="checkbox"/>		25.4		21,249	40,305
Oct-07	40,305				1,589	<input type="checkbox"/>		23.9		19,288	38,716
Nov-07	38,716	82,624	Ordered	DONATION	1,619	<input type="checkbox"/>		72.6		99,921	119,721
Dec-07	119,721				1,650	<input type="checkbox"/>		70.3		97,911	118,071
Jan-08	118,071				1,681	<input type="checkbox"/>		68.0		95,858	116,390
Feb-08	116,390				1,711	<input type="checkbox"/>		65.9		93,811	114,679
Mar-08	114,679				1,742	<input type="checkbox"/>		64.0		91,757	112,937
Apr-08	112,937				1,765	<input type="checkbox"/>		62.2		89,716	111,172
May-08	111,172				1,788	<input type="checkbox"/>		60.4		87,652	109,384
Jun-08	109,384				1,811	<input type="checkbox"/>		58.7		85,565	107,573
Jul-08	107,573				1,834	<input type="checkbox"/>		56.9		83,455	105,739
Aug-08	105,739				1,857	<input type="checkbox"/>		55.3		81,322	103,882
Sep-08	103,882				1,880	<input type="checkbox"/>		53.6		79,166	102,002
Oct-08	102,002				1,903	<input type="checkbox"/>		52.0		76,987	100,099
Nov-08	100,099				1,926	<input type="checkbox"/>		50.4		74,785	98,173
Dec-08	98,173				1,949	<input type="checkbox"/>		48.8		72,560	96,224

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Efavirenz 50mg [Stocrin/Sustiva] 30 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	17,797	15.3		3,829	17,797
Jul-07	17,797				1,728	<input type="checkbox"/>		9.1	1,561		16,069
Aug-07	16,069				1,764	<input type="checkbox"/>	11,195	14.2		3,912	25,500
Sep-07	25,500	12,336	Received	DONATION	1,799	<input type="checkbox"/>		19.6		14,017	36,037
Oct-07	36,037				1,835	<input type="checkbox"/>		18.3		11,762	34,202
Nov-07	34,202	46,860	Ordered	DONATION	1,871	<input type="checkbox"/>		41.5		56,319	79,191
Dec-07	79,191				1,906	<input type="checkbox"/>		39.8		53,981	77,285
Jan-08	77,285				1,942	<input type="checkbox"/>		38.1		51,619	75,343
Feb-08	75,343				1,978	<input type="checkbox"/>		36.5		49,245	73,365
Mar-08	73,365				2,013	<input type="checkbox"/>		35.0		46,872	71,352
Apr-08	71,352				2,040	<input type="checkbox"/>		33.5		44,508	69,312
May-08	69,312				2,067	<input type="checkbox"/>		32.1		42,117	67,245
Jun-08	67,245				2,094	<input type="checkbox"/>		30.7		39,699	65,151
Jul-08	65,151				2,121	<input type="checkbox"/>		29.3		37,254	63,030
Aug-08	63,030				2,148	<input type="checkbox"/>		28.0		34,782	60,882
Sep-08	60,882				2,175	<input type="checkbox"/>		26.7		32,283	58,707
Oct-08	58,707				2,202	<input type="checkbox"/>		25.3		29,757	56,505
Nov-08	56,505				2,229	<input type="checkbox"/>		24.1		27,204	54,276
Dec-08	54,276				2,256	<input type="checkbox"/>		22.8		24,624	52,020

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Efavirenz 600mg 30 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	50,854	1.9	220,666	-84,906	50,854
Jul-07	50,854				40,317	<input type="checkbox"/>		.3	400,863	-195,163	10,537
Aug-07	10,537				41,140	<input type="checkbox"/>	77,764	1.1	372,469	-162,654	47,161
Sep-07	47,161	43,872	Received	DONATION	41,963	<input type="checkbox"/>		1.1	378,790	-164,860	49,070
Oct-07	49,070				42,787	<input type="checkbox"/>		.1	429,817	-211,767	6,283
Nov-07	6,283	130,684	Ordered	DONATION	43,610	<input type="checkbox"/>		2.1	350,973	-128,808	93,357
Dec-07	93,357				44,433	<input type="checkbox"/>		1.1	403,636	-177,356	48,924
Jan-08	48,924				45,256	<input type="checkbox"/>		.1	457,122	-226,727	3,668
Feb-08	3,668	510,804	Planned	GOB/CMS	46,079	<input type="checkbox"/>		10.0			468,393
Mar-08	468,393				46,903	<input type="checkbox"/>		8.9	53,700		421,490
Apr-08	421,490				47,519	<input type="checkbox"/>		7.8	107,389		373,971
May-08	373,971	161,700	Planned	GOB/CMS	48,136	<input type="checkbox"/>		10.0			487,535
Jun-08	487,535				48,753	<input type="checkbox"/>		8.9	54,908		438,782
Jul-08	438,782				49,370	<input type="checkbox"/>		7.8	110,448		389,412
Aug-08	389,412	166,656	Planned	GOB/CMS	49,986	<input type="checkbox"/>		10.0			506,082
Sep-08	506,082				50,603	<input type="checkbox"/>		8.9	56,711		455,479
Oct-08	455,479				51,220	<input type="checkbox"/>		7.8	114,101		404,259
Nov-08	404,259	172,116	Planned	GOB/CMS	51,836	<input type="checkbox"/>		10.0			524,539
Dec-08	524,539				52,453	<input type="checkbox"/>		8.9	58,604		472,086

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Lamivudine 10mg/ml 240 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	65,514	10.1			65,514
Jul-07	65,514				9,670	<input type="checkbox"/>		5.7	42,826		55,844
Aug-07	55,844				9,867	<input type="checkbox"/>	11,430	5.7	43,233		57,407
Sep-07	57,407	2,700	Received	GOB/CMS	10,064	<input type="checkbox"/>		4.9	52,567	-1,262	50,043
Oct-07	50,043				10,262	<input type="checkbox"/>		3.8	64,809	-12,514	39,781
Nov-07	39,781	48	Ordered	GOB/CMS	10,459	<input type="checkbox"/>		2.8	77,190	-23,910	29,370
Dec-07	29,370				10,656	<input type="checkbox"/>		1.7	89,816	-35,551	18,714
Jan-08	18,714				10,853	<input type="checkbox"/>		.7	102,639	-47,389	7,861
Feb-08	7,861	115,500	Planned	GOB/CMS	11,050	<input type="checkbox"/>		10.0			112,311
Mar-08	112,311				11,248	<input type="checkbox"/>		8.9	12,887		101,063
Apr-08	101,063				11,395	<input type="checkbox"/>		7.8	25,762		89,668
May-08	89,668	38,815	Planned	GOB/CMS	11,543	<input type="checkbox"/>		10.0			116,940
Jun-08	116,940				11,691	<input type="checkbox"/>		8.9	13,141		105,249
Jul-08	105,249				11,839	<input type="checkbox"/>		7.8	26,460		93,410
Aug-08	93,410	39,935	Planned	GOB/CMS	11,987	<input type="checkbox"/>		10.0			121,358
Sep-08	121,358				12,135	<input type="checkbox"/>		8.9	13,607		109,223
Oct-08	109,223				12,283	<input type="checkbox"/>		7.8	27,370		96,940
Nov-08	96,940	41,300	Planned	GOB/CMS	12,431	<input type="checkbox"/>		10.0			125,809
Dec-08	125,809				12,579	<input type="checkbox"/>		8.9	14,030		113,230

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Lamivudine 150mg 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	103,248	12.1		960	103,248
Jul-07	103,248				12,657	<input type="checkbox"/>		7.0	38,559		90,591
Aug-07	90,591				12,916	<input type="checkbox"/>	27,365	8.0	26,700		105,040
Sep-07	105,040	2,500	Received	GOB/CMS	13,174	<input type="checkbox"/>		7.0	39,954		94,366
Oct-07	94,366				13,433	<input type="checkbox"/>		5.9	55,977		80,933
Nov-07	80,933				13,691	<input type="checkbox"/>		4.8	72,248	-2,503	67,242
Dec-07	67,242				13,950	<input type="checkbox"/>		3.8	88,788	-17,748	53,292
Jan-08	53,292				14,208	<input type="checkbox"/>		2.7	105,576	-33,246	39,084
Feb-08	39,084	122,490	Planned	GOB/CMS	14,467	<input type="checkbox"/>		10.0			147,107
Mar-08	147,107				14,725	<input type="checkbox"/>		8.9	16,808		132,382
Apr-08	132,382				14,919	<input type="checkbox"/>		7.8	33,667		117,463
May-08	117,463	50,760	Planned	GOB/CMS	15,113	<input type="checkbox"/>		10.0			153,110
Jun-08	153,110				15,307	<input type="checkbox"/>		8.9	17,207		137,803
Jul-08	137,803				15,501	<input type="checkbox"/>		7.8	34,648		122,302
Aug-08	122,302	52,290	Planned	GOB/CMS	15,695	<input type="checkbox"/>		10.0			158,897
Sep-08	158,897				15,889	<input type="checkbox"/>		8.9	17,822		143,008
Oct-08	143,008				16,083	<input type="checkbox"/>		7.8	35,845		126,925
Nov-08	126,925	54,090	Planned	GOB/CMS	16,277	<input type="checkbox"/>		10.0			164,738
Dec-08	164,738				16,471	<input type="checkbox"/>		8.9	18,383		148,267

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Lamivudine/Zidovudine 150/300mg 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	91,840	2.2	326,560	-117,360	91,840
Jul-07	91,840				62,126	<input type="checkbox"/>		.5	604,226	-287,256	29,714
Aug-07	29,714				63,394	<input type="checkbox"/>	130,733	1.5	549,567	-226,257	97,053
Sep-07	97,053				64,663	<input type="checkbox"/>		.5	626,920	-297,265	32,390
Oct-07	32,390	1,449	Ordered	GOB/CMS	65,931	<input type="checkbox"/>		-.5	704,082	-368,087	-32,092
Nov-07	-32,092	455,000	Ordered	AUROBINDO	67,200	<input type="checkbox"/>		5.2	328,972		355,708
Dec-07	355,708				68,468	<input type="checkbox"/>		4.1	410,120	-61,440	287,240
Jan-08	287,240				69,737	<input type="checkbox"/>		3.1	492,547	-137,522	217,503
Feb-08	217,503	575,184	Planned	GOB/CMS	71,005	<input type="checkbox"/>		10.0			721,682
Mar-08	721,682				72,274	<input type="checkbox"/>		8.9	82,832		649,408
Apr-08	649,408				73,224	<input type="checkbox"/>		7.8	165,556		576,184
May-08	576,184	249,264	Planned	GOB/CMS	74,174	<input type="checkbox"/>		10.0			751,274
Jun-08	751,274				75,124	<input type="checkbox"/>		8.9	84,590		676,150
Jul-08	676,150				76,075	<input type="checkbox"/>		7.8	170,175		600,075
Aug-08	600,075	256,704	Planned	GOB/CMS	77,025	<input type="checkbox"/>		10.0			779,754
Sep-08	779,754				77,975	<input type="checkbox"/>		8.9	87,471		701,779
Oct-08	701,779				78,926	<input type="checkbox"/>		7.8	175,907		622,853
Nov-08	622,853	265,296	Planned	GOB/CMS	79,876	<input type="checkbox"/>		10.0			808,273
Dec-08	808,273				80,826	<input type="checkbox"/>		8.9	90,313		727,447

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Lopinavir/Ritonavir 200/50mg [Aluvia] 120 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	722	.3	21,118	-10,198	722
Jul-07	722				3,244	<input type="checkbox"/>		-8	35,612	-19,067	-2,522
Aug-07	-2,522				3,310	<input type="checkbox"/>	5,515	-1	34,067	-17,192	-317
Sep-07	-317	40	Received	GOB/CMS	3,375	<input type="checkbox"/>		-1.1	38,062	-20,857	-3,652
Oct-07	-3,652				3,441	<input type="checkbox"/>		-2.0	42,153	-24,623	-7,093
Nov-07	-7,093	4,308	Ordered	GOB/CMS	3,507	<input type="checkbox"/>		-1.8	42,012	-24,152	-6,292
Dec-07	-6,292				3,572	<input type="checkbox"/>		-2.7	46,244	-28,054	-9,864
Jan-08	-9,864				3,638	<input type="checkbox"/>		-3.6	50,542	-32,022	-13,502
Feb-08	-13,502	54,880	Planned	GOB/CMS	3,704	<input type="checkbox"/>		10.0			37,674
Mar-08	37,674				3,770	<input type="checkbox"/>		8.9	4,296		33,904
Apr-08	33,904				3,820	<input type="checkbox"/>		7.8	8,616		30,084
May-08	30,084	13,000	Planned	GOB/CMS	3,870	<input type="checkbox"/>		10.0			39,214
Jun-08	39,214				3,920	<input type="checkbox"/>		8.9	4,406		35,294
Jul-08	35,294				3,970	<input type="checkbox"/>		7.8	8,876		31,324
Aug-08	31,324	13,400	Planned	GOB/CMS	4,020	<input type="checkbox"/>		10.0			40,704
Sep-08	40,704				4,070	<input type="checkbox"/>		8.9	4,566		36,634
Oct-08	36,634				4,120	<input type="checkbox"/>		7.8	9,186		32,514
Nov-08	32,514	13,880	Planned	GOB/CMS	4,170	<input type="checkbox"/>		10.0			42,224
Dec-08	42,224				4,220	<input type="checkbox"/>		8.9	4,696		38,004

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Lopinavir/Ritonavir 80/20mg/ml [Kaletra] 300 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	2,599	35.1		1,711	2,599
Jul-07	2,599				111	<input type="checkbox"/>		22.0		1,132	2,488
Aug-07	2,488				113	<input type="checkbox"/>	318	23.4		1,313	2,693
Sep-07	2,693				115	<input type="checkbox"/>		22.0		1,174	2,578
Oct-07	2,578				117	<input type="checkbox"/>		20.7		1,033	2,461
Nov-07	2,461	2,055	Ordered	GOB/CMS	119	<input type="checkbox"/>		36.3		2,945	4,397
Dec-07	4,397				122	<input type="checkbox"/>		34.5		2,787	4,275
Jan-08	4,275				124	<input type="checkbox"/>		32.9		2,639	4,151
Feb-08	4,151				126	<input type="checkbox"/>		31.4		2,489	4,025
Mar-08	4,025				128	<input type="checkbox"/>		30.0		2,337	3,897
Apr-08	3,897				130	<input type="checkbox"/>		28.8		2,195	3,767
May-08	3,767				132	<input type="checkbox"/>		27.3		2,039	3,635
Jun-08	3,635				133	<input type="checkbox"/>		26.1		1,894	3,502
Jul-08	3,502				135	<input type="checkbox"/>		24.8		1,735	3,367
Aug-08	3,367				136	<input type="checkbox"/>		23.6		1,587	3,231
Sep-08	3,231				138	<input type="checkbox"/>		22.3		1,425	3,093
Oct-08	3,093				139	<input type="checkbox"/>		21.1		1,274	2,954
Nov-08	2,954				141	<input type="checkbox"/>		19.8		1,109	2,813
Dec-08	2,813				142	<input type="checkbox"/>		18.7		955	2,671

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Nevirapine 10mg/ml [Viramune] 240 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	11,780	3.5	22,220	-5,220	11,780
Jul-07	11,780				5,049	<input type="checkbox"/>		1.3	44,789	-19,029	6,731
Aug-07	6,731				5,152	<input type="checkbox"/>	7,742	1.8	43,229	-16,954	9,321
Sep-07	9,321	2,800	Received	GOB/CMS	5,255	<input type="checkbox"/>		1.3	46,714	-19,924	6,866
Oct-07	6,866				5,359	<input type="checkbox"/>		.3	53,113	-25,803	1,507
Nov-07	1,507	59,703	Ordered	GOB/CMS	5,462	<input type="checkbox"/>		10.0			55,748
Dec-07	55,748				5,565	<input type="checkbox"/>		8.9	6,497		50,183
Jan-08	50,183				5,668	<input type="checkbox"/>		7.7	13,195		44,515
Feb-08	44,515	19,906	Planned	GOB/CMS	5,771	<input type="checkbox"/>		10.0			58,650
Mar-08	58,650				5,874	<input type="checkbox"/>		8.9	6,734		52,776
Apr-08	52,776				5,952	<input type="checkbox"/>		7.8	13,466		46,824
May-08	46,824	20,265	Planned	GOB/CMS	6,029	<input type="checkbox"/>		10.0			61,060
Jun-08	61,060				6,107	<input type="checkbox"/>		8.9	6,887		54,953
Jul-08	54,953				6,184	<input type="checkbox"/>		7.8	13,841		48,769
Aug-08	48,769	20,883	Planned	GOB/CMS	6,262	<input type="checkbox"/>		10.0			63,390
Sep-08	63,390				6,339	<input type="checkbox"/>		8.9	7,109		57,051
Oct-08	57,051				6,417	<input type="checkbox"/>		7.8	14,306		50,634
Nov-08	50,634	21,570	Planned	GOB/CMS	6,494	<input type="checkbox"/>		10.0			65,710
Dec-08	65,710				6,572	<input type="checkbox"/>		8.9	7,352		59,138

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Nevirapine 200mg 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	34,411	1.6	186,109	-75,849	34,411
Jul-07	34,411				32,744	<input type="checkbox"/>		.0	332,453	-165,393	1,667
Aug-07	1,667				33,413	<input type="checkbox"/>	73,399	1.2	299,157	-128,752	41,653
Sep-07	41,653	2,600	Received	GOB/CMS	34,081	<input type="checkbox"/>		.3	337,318	-163,573	10,172
Oct-07	10,172				34,750	<input type="checkbox"/>		-.7	378,758	-201,668	-24,578
Nov-07	-24,578	332,012	Ordered	GOB/CMS	35,418	<input type="checkbox"/>		7.5	88,854		272,016
Dec-07	272,016				36,087	<input type="checkbox"/>		6.4	131,621		235,929
Jan-08	235,929				36,756	<input type="checkbox"/>		5.3	175,067		199,173
Feb-08	199,173	218,625	Planned	GOB/CMS	37,424	<input type="checkbox"/>		10.0			380,374
Mar-08	380,374				38,093	<input type="checkbox"/>		8.9	43,659		342,281
Apr-08	342,281				38,594	<input type="checkbox"/>		7.8	87,263		303,687
May-08	303,687	131,400	Planned	GOB/CMS	39,095	<input type="checkbox"/>		10.0			395,992
Jun-08	395,992				39,596	<input type="checkbox"/>		8.9	44,574		356,396
Jul-08	356,396				40,097	<input type="checkbox"/>		7.8	89,681		316,299
Aug-08	316,299	135,300	Planned	GOB/CMS	40,598	<input type="checkbox"/>		10.0			411,001
Sep-08	411,001				41,099	<input type="checkbox"/>		8.9	46,098		369,902
Oct-08	369,902				41,600	<input type="checkbox"/>		7.8	92,708		328,302
Nov-08	328,302	139,875	Planned	GOB/CMS	42,101	<input type="checkbox"/>		10.0			426,076
Dec-08	426,076				42,602	<input type="checkbox"/>		8.9	47,546		383,474

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Ritonavir 100mg 336 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	301	27.4		169	301
Jul-07	301				17	<input type="checkbox"/>		16.7		80	284
Aug-07	284				17	<input type="checkbox"/>	123	22.9		186	390
Sep-07	390				18	<input type="checkbox"/>		20.7		156	372
Oct-07	372				18	<input type="checkbox"/>		19.7		138	354
Nov-07	354	3,200	Ordered	GOB/CMS	18	<input type="checkbox"/>		196.4		3,320	3,536
Dec-07	3,536				19	<input type="checkbox"/>		185.1		3,289	3,517
Jan-08	3,517				19	<input type="checkbox"/>		184.1		3,270	3,498
Feb-08	3,498				19	<input type="checkbox"/>		183.1		3,251	3,479
Mar-08	3,479				20	<input type="checkbox"/>		173.0		3,219	3,459
Apr-08	3,459				20	<input type="checkbox"/>		172.0		3,199	3,439
May-08	3,439				20	<input type="checkbox"/>		171.0		3,179	3,419
Jun-08	3,419				20	<input type="checkbox"/>		170.0		3,159	3,399
Jul-08	3,399				21	<input type="checkbox"/>		160.9		3,126	3,378
Aug-08	3,378				21	<input type="checkbox"/>		159.9		3,105	3,357
Sep-08	3,357				21	<input type="checkbox"/>		158.9		3,084	3,336
Oct-08	3,336				22	<input type="checkbox"/>		150.6		3,050	3,314
Nov-08	3,314				22	<input type="checkbox"/>		149.6		3,028	3,292
Dec-08	3,292				22	<input type="checkbox"/>		148.6		3,006	3,270

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Saquinavir 200mg [Invirase] 270 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	2,982	96.2		2,610	2,982
Jul-07	2,982				46	<input type="checkbox"/>		62.5		2,372	2,936
Aug-07	2,936				47	<input type="checkbox"/>	206	64.5		2,519	3,095
Sep-07	3,095				48	<input type="checkbox"/>		62.2		2,459	3,047
Oct-07	3,047				49	<input type="checkbox"/>		60.0		2,398	2,998
Nov-07	2,998	818	Ordered	GOB/CMS	50	<input type="checkbox"/>		73.8		3,154	3,766
Dec-07	3,766				51	<input type="checkbox"/>		71.4		3,091	3,715
Jan-08	3,715				52	<input type="checkbox"/>		69.1		3,027	3,663
Feb-08	3,663				53	<input type="checkbox"/>		68.1		2,974	3,610
Mar-08	3,610				54	<input type="checkbox"/>		65.9		2,908	3,556
Apr-08	3,556				54	<input type="checkbox"/>		63.7		2,842	3,502
May-08	3,502				55	<input type="checkbox"/>		61.6		2,775	3,447
Jun-08	3,447				56	<input type="checkbox"/>		60.6		2,719	3,391
Jul-08	3,391				57	<input type="checkbox"/>		58.5		2,650	3,334
Aug-08	3,334				57	<input type="checkbox"/>		56.5		2,581	3,277
Sep-08	3,277				58	<input type="checkbox"/>		55.5		2,523	3,219
Oct-08	3,219				59	<input type="checkbox"/>		53.6		2,452	3,160
Nov-08	3,160				59	<input type="checkbox"/>		51.7		2,381	3,101
Dec-08	3,101				60	<input type="checkbox"/>		49.9		2,309	3,041

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Stavudine 15mg [Zerit] 60 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	23,632	172.5		21,988	23,632
Jul-07	23,632				204	<input type="checkbox"/>		112.6		20,932	23,428
Aug-07	23,428				208	<input type="checkbox"/>	1,105	114.7		21,781	24,325
Sep-07	24,325				212	<input type="checkbox"/>		111.6		21,521	24,113
Oct-07	24,113				216	<input type="checkbox"/>		108.6		21,257	23,897
Nov-07	23,897	30,677	Ordered	GOB/CMS	221	<input type="checkbox"/>		241.6		51,653	54,353
Dec-07	54,353				225	<input type="checkbox"/>		236.4		51,380	54,128
Jan-08	54,128				229	<input type="checkbox"/>		231.3		51,103	53,899
Feb-08	53,899				233	<input type="checkbox"/>		227.4		50,834	53,666
Mar-08	53,666				237	<input type="checkbox"/>		222.6		50,549	53,429
Apr-08	53,429				240	<input type="checkbox"/>		218.9		50,273	53,189
May-08	53,189				244	<input type="checkbox"/>		214.4		49,981	52,945
Jun-08	52,945				247	<input type="checkbox"/>		210.8		49,698	52,698
Jul-08	52,698				250	<input type="checkbox"/>		207.3		49,412	52,448
Aug-08	52,448				254	<input type="checkbox"/>		203.1		49,110	52,194
Sep-08	52,194				257	<input type="checkbox"/>		199.8		48,817	51,937
Oct-08	51,937				260	<input type="checkbox"/>		196.5		48,521	51,677
Nov-08	51,677				263	<input type="checkbox"/>		193.3		48,222	51,414
Dec-08	51,414				267	<input type="checkbox"/>		189.4		47,907	51,147

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Stavudine 1mg/ml 200 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	7,060	4.7	8,090	-515	7,060
Jul-07	7,060				2,250	<input type="checkbox"/>		2.1	18,140	-6,665	4,810
Aug-07	4,810				2,295	<input type="checkbox"/>	1,389	1.7	19,506	-7,801	3,904
Sep-07	3,904				2,341	<input type="checkbox"/>		.7	22,307	-10,372	1,563
Oct-07	1,563				2,387	<input type="checkbox"/>		-.3	25,144	-12,984	-824
Nov-07	-824	9,000	Ordered	GOB/CMS	2,433	<input type="checkbox"/>		2.3	19,037	-6,647	5,743
Dec-07	5,743				2,478	<input type="checkbox"/>		1.3	21,975	-9,355	3,265
Jan-08	3,265				2,524	<input type="checkbox"/>		.3	24,959	-12,109	741
Feb-08	741	27,950	Planned	GOB/CMS	2,570	<input type="checkbox"/>		10.0			26,121
Mar-08	26,121				2,616	<input type="checkbox"/>		8.9	2,985		23,505
Apr-08	23,505				2,649	<input type="checkbox"/>		7.8	5,964		20,856
May-08	20,856	9,000	Planned	GOB/CMS	2,683	<input type="checkbox"/>		10.0			27,173
Jun-08	27,173				2,716	<input type="checkbox"/>		8.9	3,033		24,457
Jul-08	24,457				2,750	<input type="checkbox"/>		7.8	6,123		21,707
Aug-08	21,707	9,250	Planned	GOB/CMS	2,783	<input type="checkbox"/>		10.0			28,174
Sep-08	28,174				2,817	<input type="checkbox"/>		8.9	3,143		25,357
Oct-08	25,357				2,850	<input type="checkbox"/>		7.8	6,323		22,507
Nov-08	22,507	9,550	Planned	GOB/CMS	2,884	<input type="checkbox"/>		10.0			29,173
Dec-08	29,173				2,917	<input type="checkbox"/>		8.9	3,254		26,256

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Stavudine 20mg 60 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	8,608	46.0		6,364	8,608
Jul-07	8,608				279	<input type="checkbox"/>		29.3		4,921	8,329
Aug-07	8,329				284	<input type="checkbox"/>	1,468	32.8		6,033	9,513
Sep-07	9,513				290	<input type="checkbox"/>		31.3		5,683	9,223
Oct-07	9,223				296	<input type="checkbox"/>		29.7		5,315	8,927
Nov-07	8,927	11,518	Ordered	GOB/CMS	301	<input type="checkbox"/>		65.6		16,460	20,144
Dec-07	20,144				307	<input type="checkbox"/>		63.6		16,093	19,837
Jan-08	19,837				313	<input type="checkbox"/>		61.4		15,708	19,524
Feb-08	19,524				318	<input type="checkbox"/>		59.5		15,330	19,206
Mar-08	19,206				324	<input type="checkbox"/>		57.6		14,946	18,882
Apr-08	18,882				329	<input type="checkbox"/>		55.7		14,557	18,553
May-08	18,553				333	<input type="checkbox"/>		54.1		14,176	18,220
Jun-08	18,220				338	<input type="checkbox"/>		52.3		13,778	17,882
Jul-08	17,882				342	<input type="checkbox"/>		50.7		13,388	17,540
Aug-08	17,540				347	<input type="checkbox"/>		49.0		12,981	17,193
Sep-08	17,193				351	<input type="checkbox"/>		47.4		12,582	16,842
Oct-08	16,842				356	<input type="checkbox"/>		45.8		12,166	16,486
Nov-08	16,486				360	<input type="checkbox"/>		44.2		11,746	16,126
Dec-08	16,126				365	<input type="checkbox"/>		42.7		11,333	15,761

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Stavudine 30mg 60 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	29,775	3.7	49,855	-10,040	29,775
Jul-07	29,775				11,825	<input type="checkbox"/>		1.5	102,710	-42,380	17,950
Aug-07	17,950				12,066	<input type="checkbox"/>	18,705	2.0	98,481	-36,946	24,589
Sep-07	24,589				12,307	<input type="checkbox"/>		1.0	113,198	-50,458	12,282
Oct-07	12,282				12,549	<input type="checkbox"/>		.0	128,167	-64,217	-267
Nov-07	-267	53,538	Ordered	GOB/CMS	12,790	<input type="checkbox"/>		3.1	89,829	-24,674	40,481
Dec-07	40,481				13,031	<input type="checkbox"/>		2.1	105,270	-38,910	27,450
Jan-08	27,450				13,272	<input type="checkbox"/>		1.0	120,952	-53,387	14,178
Feb-08	14,178	136,710	Planned	GOB/CMS	13,514	<input type="checkbox"/>		10.0			137,374
Mar-08	137,374				13,755	<input type="checkbox"/>		8.9	15,741		123,619
Apr-08	123,619				13,936	<input type="checkbox"/>		7.8	31,487		109,683
May-08	109,683	47,430	Planned	GOB/CMS	14,117	<input type="checkbox"/>		10.0			142,996
Jun-08	142,996				14,298	<input type="checkbox"/>		8.9	16,092		128,698
Jul-08	128,698				14,479	<input type="checkbox"/>		7.8	32,381		114,219
Aug-08	114,219	48,870	Planned	GOB/CMS	14,661	<input type="checkbox"/>		10.0			148,428
Sep-08	148,428				14,842	<input type="checkbox"/>		8.9	16,644		133,586
Oct-08	133,586				15,023	<input type="checkbox"/>		7.8	33,477		118,563
Nov-08	118,563	50,580	Planned	GOB/CMS	15,204	<input type="checkbox"/>		10.0			153,939
Dec-08	153,939				15,385	<input type="checkbox"/>		8.9	17,106		138,554

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Tenofovir disoproxil fumarate 300mg 30 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	1,992	3.2	4,318	-1,163	1,992
Jul-07	1,992				937	<input type="checkbox"/>		1.1	8,505	-3,725	1,055
Aug-07	1,055				956	<input type="checkbox"/>	1,697	1.8	7,954	-3,079	1,796
Sep-07	1,796	344	Received	GOB/CMS	975	<input type="checkbox"/>		1.2	8,775	-3,805	1,165
Oct-07	1,165				994	<input type="checkbox"/>		.2	9,959	-4,894	171
Nov-07	171				1,013	<input type="checkbox"/>		-.8	11,162	-6,002	-842
Dec-07	-842				1,032	<input type="checkbox"/>		-1.8	12,384	-7,129	-1,874
Jan-08	-1,874				1,051	<input type="checkbox"/>		-2.7	13,625	-8,275	-2,925
Feb-08	-2,925	14,865	Planned	GOB/CMS	1,070	<input type="checkbox"/>		10.0			10,870
Mar-08	10,870				1,089	<input type="checkbox"/>		8.9	1,249		9,781
Apr-08	9,781				1,103	<input type="checkbox"/>		7.8	2,492		8,678
May-08	8,678	3,749	Planned	GOB/CMS	1,117	<input type="checkbox"/>		10.0			11,310
Jun-08	11,310				1,132	<input type="checkbox"/>		8.9	1,282		10,178
Jul-08	10,178				1,146	<input type="checkbox"/>		7.8	2,568		9,032
Aug-08	9,032	3,868	Planned	GOB/CMS	1,160	<input type="checkbox"/>		10.0			11,740
Sep-08	11,740				1,174	<input type="checkbox"/>		8.9	1,314		10,566
Oct-08	10,566				1,189	<input type="checkbox"/>		7.8	2,653		9,377
Nov-08	9,377	3,996	Planned	GOB/CMS	1,203	<input type="checkbox"/>		10.0			12,170
Dec-08	12,170				1,217	<input type="checkbox"/>		8.9	1,357		10,953

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Zidovudine 100mg 100 Caps

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	45,270	100.2		39,846	45,270
Jul-07	45,270				672	<input type="checkbox"/>		65.0		36,366	44,598
Aug-07	44,598				686	<input type="checkbox"/>	10,498	77.8		46,022	54,410
Sep-07	54,410				700	<input type="checkbox"/>		75.3		45,154	53,710
Oct-07	53,710				713	<input type="checkbox"/>		72.9		44,273	52,997
Nov-07	52,997	24,421	Ordered	GOB/CMS	727	<input type="checkbox"/>		103.5		67,799	76,691
Dec-07	76,691				741	<input type="checkbox"/>		100.6		66,890	75,950
Jan-08	75,950				755	<input type="checkbox"/>		97.8		65,967	75,195
Feb-08	75,195				769	<input type="checkbox"/>		95.3		65,054	74,426
Mar-08	74,426				783	<input type="checkbox"/>		92.9		64,127	73,643
Apr-08	73,643				793	<input type="checkbox"/>		90.7		63,214	72,850
May-08	72,850				804	<input type="checkbox"/>		88.5		62,278	72,046
Jun-08	72,046				814	<input type="checkbox"/>		86.4		61,344	71,232
Jul-08	71,232				825	<input type="checkbox"/>		84.3		60,387	70,407
Aug-08	70,407				835	<input type="checkbox"/>		82.3		59,432	69,572
Sep-08	69,572				846	<input type="checkbox"/>		80.3		58,454	68,726
Oct-08	68,726				856	<input type="checkbox"/>		78.4		57,478	67,870
Nov-08	67,870				867	<input type="checkbox"/>		76.4		56,479	67,003
Dec-08	67,003				877	<input type="checkbox"/>		74.6		55,482	66,126

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Zidovudine 10mg/ml [Retrovir] 200 ml

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	23,424	2.4	75,936	-26,256	23,424
Jul-07	23,424				14,754	<input type="checkbox"/>		.6	141,880	-66,605	8,670
Aug-07	8,670				15,055	<input type="checkbox"/>	11,425	.3	148,510	-71,735	5,040
Sep-07	5,040	1,200	Received	GOB/CMS	15,356	<input type="checkbox"/>		-6	165,676	-87,396	-9,116
Oct-07	-9,116				15,656	<input type="checkbox"/>		-1.6	184,342	-104,557	-24,772
Nov-07	-24,772	2,415	Ordered	GOB/CMS	15,957	<input type="checkbox"/>		-2.4	200,894	-119,604	-38,314
Dec-07	-38,314				16,258	<input type="checkbox"/>		-3.3	220,162	-137,367	-54,572
Jan-08	-54,572				16,559	<input type="checkbox"/>		-4.2	239,731	-155,431	-71,131
Feb-08	-71,131	259,356	Planned	GOB/CMS	16,860	<input type="checkbox"/>		10.0			171,365
Mar-08	171,365				17,161	<input type="checkbox"/>		8.9	19,656		154,204
Apr-08	154,204				17,387	<input type="checkbox"/>		7.8	39,303		136,817
May-08	136,817	59,184	Planned	GOB/CMS	17,612	<input type="checkbox"/>		10.0			178,389
Jun-08	178,389				17,838	<input type="checkbox"/>		8.9	20,089		160,551
Jul-08	160,551				18,064	<input type="checkbox"/>		7.8	40,413		142,487
Aug-08	142,487	60,960	Planned	GOB/CMS	18,290	<input type="checkbox"/>		10.0			185,157
Sep-08	185,157				18,516	<input type="checkbox"/>		8.9	20,769		166,641
Oct-08	166,641				18,741	<input type="checkbox"/>		7.8	41,770		147,900
Nov-08	147,900	63,000	Planned	GOB/CMS	18,967	<input type="checkbox"/>		10.0			191,933
Dec-08	191,933				19,193	<input type="checkbox"/>		8.9	21,450		172,740

Stock Status By Month

Report Period: Jan 2007 - Dec 2008

Product: Zidovudine 300mg [Retrovir] 60 Tabs

Desired months of stock = 10
 Minimum = 5 Maximum = 12

Month	Beginning Balance	-----Shipments -----			----Consumption----		Stock Adjustment	Stock in Months	Desired Stock	Shortfall / Surplus	Ending Balance
		Quantity	Status	Supplier	Amount	Actual?					
Jun-07					0	<input type="checkbox"/>	10,354	10.8			10,354
Jul-07	10,354				1,421	<input type="checkbox"/>		6.2	5,567		8,933
Aug-07	8,933				1,450	<input type="checkbox"/>	2,831	7.0	4,476		10,314
Sep-07	10,314				1,479	<input type="checkbox"/>		5.9	6,245		8,835
Oct-07	8,835				1,508	<input type="checkbox"/>		4.8	8,043	-358	7,327
Nov-07	7,327	54,277	Ordered	GOB/CMS	1,537	<input type="checkbox"/>		38.4		41,275	60,067
Dec-07	60,067				1,566	<input type="checkbox"/>		36.7		39,361	58,501
Jan-08	58,501				1,595	<input type="checkbox"/>		35.0		37,418	56,906
Feb-08	56,906				1,624	<input type="checkbox"/>		33.5		35,482	55,282
Mar-08	55,282				1,653	<input type="checkbox"/>		32.0		33,529	53,629
Apr-08	53,629				1,675	<input type="checkbox"/>		30.6		31,590	51,954
May-08	51,954				1,697	<input type="checkbox"/>		29.2		29,629	50,257
Jun-08	50,257				1,719	<input type="checkbox"/>		27.9		27,646	48,538
Jul-08	48,538				1,741	<input type="checkbox"/>		26.5		25,641	46,797
Aug-08	46,797				1,763	<input type="checkbox"/>		25.2		23,614	45,034
Sep-08	45,034				1,785	<input type="checkbox"/>		23.9		21,565	43,249
Oct-08	43,249				1,807	<input type="checkbox"/>		22.7		19,494	41,442
Nov-08	41,442				1,829	<input type="checkbox"/>		21.4		17,401	39,613
Dec-08	39,613				1,851	<input type="checkbox"/>		20.2		15,286	37,762

Appendix 3: List of Regimens by Condition and Category

List of Regimens by Condition and Category

Data Set: Botswana Quantification September 200 Description:

Data Set Population: 0

Category	Condition	% of Data Set Population	Number affected by condition			
ART						
Adult 1st Line - ART Sites		0.00%	0			
	Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
	AZT/3TC/NVP		Adults	38.10%	0	
	D4T/3TC/EFV		Adults	8.10%	0	
	D4T/3TC/NVP		Adults	6.00%	0	
	AZT/3TC/EFV		Adults	47.70%	0	
	DDI/3TC/EFV		Adults	0.10%	0	
	Total Percent Treated by Regimens			100.0%		
Adult 1st Line - Nyangambwe Hospit		0.00%	0			
	Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
	D4T/3TC/EFV		Adults	10.00%	0	
	AZT/3TC/EFV		Adults	51.29%	0	
	D4T/3TC/NVP		Adults	8.13%	0	
	AZT/3TC/NVP		Adults	30.58%	0	
	Total Percent Treated by Regimens			100.0%		
Adult 1st Line - Princess Marina Hos		0.00%	0			
	Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
	TDF/3TC/NVP		Adults	1.10%	0	
	D4T/3TC/EFV		Adults	4.58%	0	

List of Regimens by Condition and Category

Data Set: Botswana Quantification September 200 Description:

Data Set Population: 0

Category	Condition	% of Data Set Population	Number affected by condition
	AZT/3TC/EFV		Adults 44.75% 0
	D4T/3TC/NVP		Adults 6.29% 0
	DDI/3TC/EFV		Adults 0.20% 0
	TDF/3TC/EFV		Adults 1.04% 0
	AZT/3TC/NVP		Adults 42.04% 0
Total Percent Treated by Regimens			100.0%
Adult 2nd Line - ART Sites		0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/LPV-r		Adults	15.68%	0	
D4T/3TC/LPV-r		Adults	1.74%	0	
TDF/3TC/LPV-r		Adults	3.83%	0	
ABC/DDI/LPV-r		Adults	4.18%	0	
D4T/DDI/LPV-r		Adults	70.73%	0	
AZT/DDI/LPV-r		Adults	3.83%	0	
Total Percent Treated by Regimens			100.0%		
Adult 2nd Line - Nyangambwe Hospit		0.00%	0		

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
ABC/3TC/LPV-r		Adults	5.71%	0	
AZT/3TC/LPV-r		Adults	16.67%	0	
D4T/3TC/LPV-r		Adults	6.19%	0	

List of Regimens by Condition and Category

Data Set: Botswana Quantification September 200 Description:

Data Set Population: 0

Category	Condition	% of Data Set Population	Number affected by condition
	D4T/DDI/LPV-r		Adults 57.95% 0
	ABC/3TC/SQV-r		Adults 1.00% 0
	TDF/3TC/SQV/LPV-r		Adults 2.00% 0
	3TC/DDI/LPV-r		Adults 10.48% 0
Total Percent Treated by Regimens			100.0%
Adult 2nd Line - Princess Marina Hos		0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
ABC/DDI/LPV-r		Adults	4.33%	0	
AZT/DDI/LPV-r		Adults	2.16%	0	
D4T/DDI/LPV-r		Adults	29.00%	0	
TDF/3TC/LPV-r		Adults	21.06%	0	
TDF/DDI/LPV-r		Adults	7.87%	0	
TDF/3TC/SQV/LPV-r		Adults	2.00%	0	
D4T/3TC/LPV-r		Adults	1.97%	0	
ABC/TDF/LPV-r		Adults	8.86%	0	
ABC/3TC/SQV-r		Adults	1.09%	0	
AZT/3TC/LPV-r		Adults	21.65%	0	

Total Percent Treated by Regimens			100.0%
Pediatric 1st Line - ART Sites		0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

List of Regimens by Condition and Category

Data Set: Botswana Quantification September 200 Description:

Data Set Population: 0

Category	Condition	% of Data Set Population	Number affected by condition
	AZT/3TC/NVP SOL		Pediatric 20.44% 0
	D4T/3TCSOL/EFV		Pediatric 2.96% 0
	D4T/3TC/NVP SOL		Pediatric 10.10% 0
	AZT/3TCSOL/EFV		Pediatric 66.50% 0
Total Percent Treated by Regimens			100.0%
Pediatric 1st Line - Nyangambwe Hos		0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 15/3TC/EFV		Pediatric	1.02%	0	
D4T 15/3TC/NVPSOL		Pediatric	6.33%	0	D4T 15mg is the only solid dosage form in this regimen
AZT/3TCSOL/EFV		Pediatric	3.88%	0	
D4T 30/3TC/EFV		Pediatric	2.45%	0	
D4T 20/3TC/NVP		Pediatric	3.47%	0	
D4T 15/3TC/NVP		Pediatric	1.63%	0	
AZT/3TC/NVP SOL		Pediatric	11.02%	0	
AZT/3TC/NVP		Pediatric	7.35%	0	
AZT/3TC/EFV		Pediatric	58.37%	0	
D4T 20/3TC/EFV		Pediatric	4.49%	0	
Total Percent Treated by Regimens			100.0%		
Pediatric 1st Line - Princess Marina		0.00%		0	

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

List of Regimens by Condition and Category

Data Set: Botswana Quantification September 200 Description:

Data Set Population: 0

Category	Condition	% of Data Set Population	Number affected by condition	
	AZT/3TC/NVP	Pediatric	43.25%	0
	D4T 20/3TC/NVP	Pediatric	6.13%	0
	AZT/3TCSOL/EFV	Pediatric	0.31%	0
	AZT/3TC/NVP SOL	Pediatric	12.88%	0
	D4T 30/3TC/EFV	Pediatric	2.15%	0
	D4T 15/3TC/NVP	Pediatric	2.45%	0
	D4T/3TC/NVP SOL	Pediatric	2.76%	0
	AZT/3TC/EFV	Pediatric	28.53%	0
	D4T 20/3TC/EFV	Pediatric	1.53%	0

Total Percent Treated by Regimens 100.0%

Pediatric 2nd Line - ART Sites 0.00% 0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/LPV-Rsol		Pediatric	35.71%	0	
D4T/DDI/LPV-Rsol		Pediatric	64.29%	0	

Total Percent Treated by Regimens 100.0%

Pediatric 2nd Line - Nyangambwe Ho 0.00% 0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T30/DDI/LPV-r		Pediatric	42.86%	0	
D4T 15/DDI/LPV-r		Pediatric	14.29%	0	
D4T 20/DDI/LPV-r		Pediatric	42.86%	0	

List of Regimens by Condition and Category

Data Set: Botswana Quantification September 200 Description:

Data Set Population: 0

Category	Condition	% of Data Set Population	Number affected by condition		
Total Percent Treated by Regimens			100.0%		
	Pediatric 2nd Line - Princess Marina	0.00%	0		
Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/LPV-R		Pediatric	14.63%	0	
D4T 30/ABC/LPV-R		Pediatric	9.76%	0	
D4T 30/DDI/LPV-R		Pediatric	12.20%	0	
D4T 20/DDI/LPV-R		Pediatric	13.41%	0	
D4T 20/ABC/LPV-R		Pediatric	10.98%	0	
D4T15/DDI/LPV-R		Pediatric	8.54%	0	
D4T 15/3TC/LPV-RSOL		Pediatric	13.41%	0	
AZT/ABC/LPV-R		Pediatric	8.54%	0	
AZT100/DDI 100/LPV-R		Pediatric	8.54%	0	
Total Percent Treated by Regimens			100.0%		

Appendix 4: Regimen Episodic Costs

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 1st Line - ART Sites	0.00%	0
------------	-----------------------------------	--------------	----------

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/EFV		Adults	47.70%	0	
--------------------	--	--------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine-Zidovudine 150+300MG/tab	1.0	tab	2	365	100.0%	730.0	225.08 US
						<u>376.19</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	376.19	0.00	376.19
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 1st Line - ART Sites	0.00%	0
------------	-----------------------------------	--------------	----------

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/NVP		Adults	38.10%	0	
--------------------	--	--------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine-Zidovudine 150+300MG/tab	1.0	tab	2	365	100.0%	730.0	225.08 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
						<u>608.83</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	608.83	0.00	608.83
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - ART Sites	<i>0.00%</i>	<i>0</i>

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/EFV		Adults	8.10%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						289.81	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	289.81	0.00	289.81
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - ART Sites	<i>0.00%</i>	<i>0</i>

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/NVP		Adults	6.00%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						<u>522.44</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	522.44	0.00	522.44
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
DDI/3TC/EFV		Adults	0.10%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
						497.06	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	497.06	0.00	497.06
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
ABC/DDI/LPV-r		Adults	4.18%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
						1,663.60	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,663.60	0.00	1,663.60
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/LPV-r		Adults	15.68%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Zidovudine [Retrovir] 300MG/tab	1.0	tab	2	365	100.0%	730.0	211.70 US
						781.10	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	781.10	0.00	781.10
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - ART Sites	0.00%	0
-----	----------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/DDI/LPV-r		Adults	3.83%	0	
---------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Zidovudine [Retrovir] 300MG/tab	1.0	tab	2	365	100.0%	730.0	211.70 US
						988.35	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	988.35	0.00	988.35
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - ART Sites	0.00%	0
------------	-----------------------------------	--------------	----------

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T/3TC/LPV-r		Adults	1.74%	0	
----------------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						<u>638.75</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	638.75	0.00	638.75
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/DDI/LPV-r		Adults	70.73%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						845.99	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	845.99	0.00	845.99
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/3TC/LPV-r		Adults	3.83%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						797.52	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	797.52	0.00	797.52
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/LPV-Rsol		Pediatrics	35.71%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Lopinavir-Ritonavir [Kaletra] 80+20MG/ml	3.0	ml	2	365	100.0%	2,190.0	300.03 US
Stavudine 1MG/ml	10.0	ml	2	365	100.0%	7,300.0	62.22 US
						526.01	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	526.01	0.00	526.01
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - ART Sites	0.00%	0
-----	--------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T/DDI/LPV-Rsol		Pediatrics	64.29%	0	
------------------	--	------------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 10MG/ml	10.0	ml	2	365	100.0%	7,300.0	459.54 US
Lopinavir-Ritonavir [Kaletra] 80+20MG/ml	3.0	ml	2	365	100.0%	2,190.0	300.03 US
Stavudine 1MG/ml	10.0	ml	2	365	100.0%	7,300.0	62.22 US
						821.79	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	821.79	0.00	821.79
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/EFV		Pediatrics	58.37%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz [Stocrin/Sustiva] 50MG/cap	1.0	cap	1	365	160.0%	584.0	67.55 US
Efavirenz 200MG/cap	1.0	cap	1	365	120.0%	438.0	77.87 US
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Zidovudine [Retrovir] 300MG/tab	0.5	tab	2	365	100.0%	365.0	105.85 US
Zidovudine 100MG/cap	1.0	cap	2	365	10.0%	73.0	11.51 US
Zidovudine 100MG/cap	2.0	cap	2	365	30.0%	438.0	69.07 US
						366.53	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	366.53	0.00	366.53
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/NVP		Pediatrics	7.35%	0	
-------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Nevirapine 200MG/tab	1.0	tab	2	365	25.0%	182.5	95.94 US
Nevirapine 200MG/tab	0.5	tab	2	365	75.0%	273.8	143.90 US
Zidovudine [Retrovir] 300MG/tab	0.5	tab	2	365	100.0%	365.0	105.85 US
Zidovudine 100MG/cap	2.0	cap	2	365	30.0%	438.0	69.07 US
Zidovudine 100MG/cap	1.0	cap	2	365	10.0%	73.0	11.51 US
						460.95	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	460.95	0.00	460.95
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/NVP SOL		Pediatrics	11.02%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Nevirapine [Viramune] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	959.36 US
Zidovudine [Retrovir] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	259.15 US
						<u>1,382.27</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,382.27	0.00	1,382.27
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TCSOL/EFV		Pediatrics	3.88%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 200MG/cap	1.0	cap	1	365	100.0%	365.0	64.89 US
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Zidovudine [Retrovir] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	259.15 US
						487.80	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	487.80	0.00	487.80
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 15/3TC/EFV		Pediatrics	1.02%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz [Stocrin/Sustiva] 50MG/cap	1.0	cap	1	365	160.0%	584.0	67.55 US
Efavirenz 200MG/cap	1.0	cap	1	365	120.0%	438.0	77.87 US
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						214.64	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	214.64	0.00	214.64
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 15/3TC/NVP		Pediatrics	1.63%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Nevirapine 200MG/tab	0.5	tab	2	365	75.0%	273.8	143.90 US
Nevirapine 200MG/tab	1.0	tab	2	365	25.0%	182.5	95.94 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						309.07	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	309.07	0.00	309.07
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 15/3TC/NVPSOL		Pediatrics	6.33%	0	D4T 15mg is the only solid dosage form in this regimen

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Nevirapine [Viramune] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	959.36 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						1,157.67	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,157.67	0.00	1,157.67
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 20/3TC/EFV		Pediatrics	4.49%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz [Stocrin/Sustiva] 50MG/cap	1.0	cap	1	365	160.0%	584.0	67.55 US
Efavirenz 200MG/cap	1.0	cap	1	365	120.0%	438.0	77.87 US
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						249.44	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	249.44	0.00	249.44
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 20/3TC/NVP		Pediatrics	3.47%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Nevirapine 200MG/tab	1.0	tab	2	365	25.0%	182.5	95.94 US
Nevirapine 200MG/tab	0.5	tab	2	365	75.0%	273.8	143.90 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						343.86	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	343.86	0.00	343.86
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 30/3TC/EFV		Pediatrics	2.45%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Efavirenz 200MG/cap	2.0	cap	1	365	100.0%	730.0	129.78 US
Lamivudine 150MG/tab	1.0	tab	2	365	75.0%	547.5	52.01 US
Lamivudine 150MG/tab	0.5	tab	2	365	25.0%	91.3	8.67 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						259.81	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	259.81	0.00	259.81
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/EFV		Adults	44.75%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine-Zidovudine 150+300MG/tab	1.0	tab	2	365	100.0%	730.0	225.08 US
						<u>376.19</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	376.19	0.00	376.19
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 1st Line - Princess Marina Hos	0.00%	0
------------	---	--------------	----------

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/NVP		Adults	42.04%	0	
--------------------	--	--------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine-Zidovudine 150+300MG/tab	1.0	tab	2	365	100.0%	730.0	225.08 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
						608.83	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	608.83	0.00	608.83
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/EFV		Adults	4.58%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						289.81	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	289.81	0.00	289.81
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/NVP		Adults	6.29%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						522.44	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	522.44	0.00	522.44
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
DDI/3TC/EFV		Adults	0.20%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
						497.06	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	497.06	0.00	497.06
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/3TC/EFV		Adults	1.04%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						448.58	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	448.58	0.00	448.58
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/3TC/NVP		Adults	1.10%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						681.22	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	681.22	0.00	681.22
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 1st Line - Nyangambwe Hospit	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/EFV		Adults	51.29%	0	
-------------	--	--------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine-Zidovudine 150+300MG/tab	1.0	tab	2	365	100.0%	730.0	225.08 US
						<u>376.19</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	376.19	0.00	376.19
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/NVP		Adults	30.58%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Lamivudine-Zidovudine 150+300MG/tab	1.0	tab	2	365	100.0%	730.0	225.08 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
						608.83	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	608.83	0.00	608.83
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 1st Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/EFV		Adults	10.00%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 600MG/tab	1.0	tab	1	365	100.0%	365.0	151.11 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						289.81	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	289.81	0.00	289.81
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 1st Line - Nyangambwe Hospit	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T/3TC/NVP		Adults	8.13%	0	
-------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Nevirapine 200MG/tab	1.0	tab	2	365	100.0%	730.0	383.74 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						522.44	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	522.44	0.00	522.44
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
3TC/DDI/LPV-r		Adults	10.48%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
						846.00	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	846.00	0.00	846.00
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0
-----	------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

ABC/3TC/LPV-r		Adults	5.71%	0	
---------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
						1,456.35	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,456.35	0.00	1,456.35
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
ABC/3TC/SQV-r		Adults	1.00%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Ritonavir 100MG/cap	4.0	cap	2	365	100.0%	2,920.0	334.40 US
Saquinavir [Invirase] 200MG/cap	5.0	cap	2	365	100.0%	3,650.0	1,035.36 US
						2,326.06	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	2,326.06	0.00	2,326.06
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/LPV-r		Adults	16.67%	0	

Medicines

<i>Product</i>	<i>Units/Dose</i>	<i>Units</i>	<i>Doses/Day</i>	<i>Num Days</i>	<i>% Treated</i>	<i>Units/Episode</i>	<i>Episode Cost</i>
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Zidovudine [Retrovir] 300MG/tab	1.0	tab	2	365	100.0%	730.0	211.70 US
						781.10	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	781.10	0.00	781.10
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/LPV-r		Adults	6.19%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						638.75	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	638.75	0.00	638.75
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/DDI/LPV-r		Adults	57.95%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						845.99	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	845.99	0.00	845.99
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Nyangambwe Hospit	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/3TC/SQV/LPV-r		Adults	2.00%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Saquinavir [Invirase] 200MG/cap	2.0	cap	2	365	100.0%	1,460.0	414.14 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						1,211.67	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,211.67	0.00	1,211.67
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - Princess Marina Hos	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

ABC/3TC/SQV-r		Adults	1.09%	0	
---------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Ritonavir 100MG/cap	4.0	cap	2	365	100.0%	2,920.0	334.40 US
Saquinavir [Invirase] 200MG/cap	5.0	cap	2	365	100.0%	3,650.0	1,035.36 US
						2,326.06	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	2,326.06	0.00	2,326.06
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
ABC/DDI/LPV-r		Adults	4.33%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
						1,663.60	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,663.60	0.00	1,663.60
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - Princess Marina Hos	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

ABC/TDF/LPV-r		Adults	8.86%	0	
---------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						1,615.13	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,615.13	0.00	1,615.13
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - Princess Marina Hos	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/LPV-r		Adults	21.65%	0	
---------------	--	--------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Zidovudine [Retrovir] 300MG/tab	1.0	tab	2	365	100.0%	730.0	211.70 US
						<u>781.10</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	781.10	0.00	781.10
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - Princess Marina Hos	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/DDI/LPV-r		Adults	2.16%	0	
---------------	--	--------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Zidovudine [Retrovir] 300MG/tab	1.0	tab	2	365	100.0%	730.0	211.70 US
						988.35	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	988.35	0.00	988.35
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/LPV-r		Adults	1.97%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						638.75	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	638.75	0.00	638.75
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Adult 2nd Line - Princess Marina Hos	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T/DDI/LPV-r		Adults	29.00%	0	
---------------	--	--------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC [Videx EC] 400MG/cap	1.0	cap	1	365	20.0%	73.0	57.60 US
Didanosine EC 250MG/cap	1.0	cap	1	365	80.0%	292.0	219.00 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						845.99	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	845.99	0.00	845.99
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/3TC/LPV-r		Adults	21.06%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						797.52	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	797.52	0.00	797.52
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/3TC/SQV/LPV-r		Adults	2.00%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	100.0%	730.0	69.35 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Saquinavir [Invirase] 200MG/cap	2.0	cap	2	365	100.0%	1,460.0	414.14 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						1,211.67	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,211.67	0.00	1,211.67
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Adult 2nd Line - Princess Marina Hos	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
TDF/DDI/LPV-r		Adults	7.87%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine EC 250MG/cap	1.0	cap	1	365	100.0%	365.0	273.75 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Tenofovir disoproxil fumarate 300MG/tab	1.0	tab	1	365	100.0%	365.0	228.13 US
						1,001.92	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,001.92	0.00	1,001.92
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/NVP SOL		Pediatrics	20.44%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Nevirapine [Viramune] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	959.36 US
Zidovudine [Retrovir] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	259.15 US
						<u>1,382.27</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,382.27	0.00	1,382.27
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - ART Sites	0.00%	0
-----	--------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TCSOL/EFV		Pediatrics	66.50%	0	
----------------	--	------------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 200MG/cap	1.0	cap	1	365	100.0%	365.0	64.89 US
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Zidovudine [Retrovir] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	259.15 US
						487.80	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	487.80	0.00	487.80
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - ART Sites	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/NVP SOL		Pediatrics	10.10%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Nevirapine [Viramune] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	959.36 US
Stavudine 1MG/ml	10.0	ml	2	365	100.0%	7,300.0	62.22 US
						1,185.34	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,185.34	0.00	1,185.34
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - ART Sites	0.00%	0
-----	--------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T/3TCSOL/EFV		Pediatrics	2.96%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 200MG/cap	1.0	cap	1	365	100.0%	365.0	64.89 US
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Stavudine 1MG/ml	10.0	ml	2	365	100.0%	7,300.0	62.22 US
						<u>290.87</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	290.87	0.00	290.87
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/3TC/LPV-R		Pediatrics	14.63%	0	
---------------	--	------------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	1.0	tab	2	365	25.0%	182.5	17.34 US
Lamivudine 150MG/tab	0.5	tab	2	365	75.0%	273.8	26.01 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	75.0%	547.5	187.52 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	25.0%	365.0	125.01 US
Zidovudine [Retrovir] 300MG/tab	0.5	tab	2	365	100.0%	365.0	105.85 US
Zidovudine 100MG/cap	2.0	cap	2	365	30.0%	438.0	69.07 US
Zidovudine 100MG/cap	1.0	cap	2	365	10.0%	73.0	11.51 US
						542.31	US

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	<i>0.00%</i>	<i>0</i>
------------	---	--------------	----------

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	542.31	0.00	542.31
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

AZT/ABC/LPV-R		Pediatrics	8.54%	0	
---------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir [Ziagen] 20MG/ml	8.0	ml	2	365	25.0%	1,460.0	190.53 US
Abacavir 300MG/tab	1.0	tab	2	365	25.0%	182.5	221.74 US
Abacavir 300MG/tab	0.5	tab	2	365	50.0%	182.5	221.74 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	25.0%	365.0	125.01 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	75.0%	547.5	187.52 US
Zidovudine [Retrovir] 300MG/tab	0.5	tab	2	365	100.0%	365.0	105.85 US
Zidovudine 100MG/cap	1.0	cap	2	365	10.0%	73.0	11.51 US
Zidovudine 100MG/cap	2.0	cap	2	365	30.0%	438.0	69.07 US
						<u>1,132.97</u>	US

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	<i>0.00%</i>	<i>0</i>
------------	---	--------------	----------

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,132.97	0.00	1,132.97
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT100/DDI 100/LPV-R		Pediatrics	8.54%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	100.0%	1,460.0	349.50 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	100.0%	730.0	250.02 US
Zidovudine 100MG/cap	1.0	cap	2	365	100.0%	730.0	115.12 US
						714.64	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	714.64	0.00	714.64
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 15/3TC/LPV-RSOL		Pediatrics	13.41%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Lopinavir-Ritonavir [Kaletra] 80+20MG/ml	3.0	ml	2	365	100.0%	2,190.0	300.03 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						498.35	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	498.35	0.00	498.35
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 20/ABC/LPV-R		Pediatrics	10.98%	0	
------------------	--	------------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir [Ziagen] 20MG/ml	8.0	ml	2	365	25.0%	1,460.0	190.53 US
Abacavir 300MG/tab	0.5	tab	2	365	75.0%	273.8	332.61 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	100.0%	730.0	250.02 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						842.51	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	842.51	0.00	842.51
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 20/DDI/LPV-R		Pediatrics	13.41%	0	
------------------	--	------------	--------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	100.0%	1,460.0	349.50 US
Didanosine 25MG/tab	1.0	tab	2	365	25.0%	182.5	43.41 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	100.0%	730.0	250.02 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						712.28	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	712.28	0.00	712.28
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 30/ABC/LPV-R		Pediatrics	9.76%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Abacavir 300MG/tab	1.0	tab	2	365	100.0%	730.0	886.95 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						<u>1,456.35</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,456.35	0.00	1,456.35
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 30/DDI/LPV-R		Pediatrics	12.20%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	75.0%	1,095.0	262.12 US
Didanosine 100MG/tab	1.0	tab	2	365	100.0%	730.0	185.17 US
Didanosine 25MG/tab	1.0	tab	2	365	25.0%	182.5	43.41 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						1,060.10	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,060.10	0.00	1,060.10
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 2nd Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T15/DDI/LPV-R		Pediatrics	8.54%	0	
-----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	100.0%	1,460.0	349.50 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	100.0%	730.0	250.02 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						634.08	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	634.08	0.00	634.08
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/EFV		Pediatrics	28.53%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz [Stocrin/Sustiva] 50MG/cap	1.0	cap	1	365	160.0%	584.0	67.55 US
Efavirenz 200MG/cap	1.0	cap	1	365	120.0%	438.0	77.87 US
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Zidovudine [Retrovir] 300MG/tab	0.5	tab	2	365	100.0%	365.0	105.85 US
Zidovudine 100MG/cap	2.0	cap	2	365	30.0%	438.0	69.07 US
Zidovudine 100MG/cap	1.0	cap	2	365	10.0%	73.0	11.51 US
						366.53	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	366.53	0.00	366.53
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/NVP		Pediatrics	43.25%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Nevirapine 200MG/tab	0.5	tab	2	365	75.0%	273.8	143.90 US
Nevirapine 200MG/tab	1.0	tab	2	365	25.0%	182.5	95.94 US
Zidovudine [Retrovir] 300MG/tab	0.5	tab	2	365	100.0%	365.0	105.85 US
Zidovudine 100MG/cap	1.0	cap	2	365	10.0%	73.0	11.51 US
Zidovudine 100MG/cap	2.0	cap	2	365	30.0%	438.0	69.07 US
						460.95	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	460.95	0.00	460.95
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TC/NVP SOL		Pediatrics	12.88%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	5.0	ml	2	365	100.0%	3,650.0	102.35 US
Nevirapine [Viramune] 10MG/ml	10.0	ml	2	365	100.0%	7,300.0	799.46 US
Zidovudine [Retrovir] 10MG/ml	10.0	ml	2	365	100.0%	7,300.0	215.96 US
						<u>1,117.78</u>	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,117.78	0.00	1,117.78
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
AZT/3TCSOL/EFV		Pediatrics	0.31%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 200MG/cap	1.0	cap	1	365	100.0%	365.0	64.89 US
Lamivudine 10MG/ml	5.0	ml	2	365	100.0%	3,650.0	102.35 US
Zidovudine [Retrovir] 10MG/ml	10.0	ml	2	365	100.0%	7,300.0	215.96 US
						383.20	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	383.20	0.00	383.20
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 15/3TC/NVP		Pediatrics	2.45%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Nevirapine 200MG/tab	1.0	tab	2	365	25.0%	182.5	95.94 US
Nevirapine 200MG/tab	0.5	tab	2	365	75.0%	273.8	143.90 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						309.07	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	309.07	0.00	309.07
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 20/3TC/EFV		Pediatrics	1.53%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz [Stocrin/Sustiva] 50MG/cap	1.0	cap	1	365	160.0%	584.0	67.55 US
Efavirenz 200MG/cap	1.0	cap	1	365	120.0%	438.0	77.87 US
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						249.44	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	249.44	0.00	249.44
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 20/3TC/NVP		Pediatrics	6.13%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 150MG/tab	0.5	tab	2	365	100.0%	365.0	34.67 US
Nevirapine 200MG/tab	0.5	tab	2	365	75.0%	273.8	143.90 US
Nevirapine 200MG/tab	1.0	tab	2	365	25.0%	182.5	95.94 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						343.86	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	343.86	0.00	343.86
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
----------	-----------	---------	------------------

ART	Pediatric 1st Line - Princess Marina	0.00%	0
-----	--------------------------------------	-------	---

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
---------	---------------	---------------	-----------------	----------------	---------------

D4T 30/3TC/EFV		Pediatrics	2.15%	0	
----------------	--	------------	-------	---	--

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Efavirenz 200MG/cap	2.0	cap	1	365	100.0%	730.0	129.78 US
Lamivudine 150MG/tab	0.5	tab	2	365	25.0%	91.3	8.67 US
Lamivudine 150MG/tab	1.0	tab	2	365	75.0%	547.5	52.01 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						259.81	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	259.81	0.00	259.81
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 1st Line - Princess Marina	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T/3TC/NVP SOL		Pediatrics	2.76%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Lamivudine 10MG/ml	8.0	ml	2	365	100.0%	5,840.0	163.76 US
Nevirapine [Viramune] 10MG/ml	12.0	ml	2	365	100.0%	8,760.0	959.36 US
Stavudine 1MG/ml	10.0	ml	2	365	100.0%	7,300.0	62.22 US
						1,185.34	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,185.34	0.00	1,185.34
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 15/DDI/LPV-r		Pediatrics	14.29%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	100.0%	1,460.0	349.50 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	100.0%	730.0	250.02 US
Stavudine [Zerit] 15MG/cap	1.0	cap	2	365	100.0%	730.0	34.55 US
						634.08	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	634.08	0.00	634.08
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T 20/DDI/LPV-r		Pediatrics	42.86%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	100.0%	1,460.0	349.50 US
Didanosine 25MG/tab	1.0	tab	2	365	25.0%	182.5	43.41 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	1.0	tab	2	365	100.0%	730.0	250.02 US
Stavudine 20MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						712.28	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	712.28	0.00	712.28
Data Set	0.00	0.00	0.00

Regimen Episodic Costs

Regimens as Percent of Treatments

Data Set: Botswana Quantification September 2007

Description:

Data Set Population: 0

Price Type: Central Medical Stores

Category	Condition	Percent	Condition Number
ART	Pediatric 2nd Line - Nyangambwe Ho	0.00%	0

Regimen	Level of Care	Patient Group	Percent Treated	Number Treated	Regimen Notes
D4T30/DDI/LPV-r		Pediatrics	42.86%	0	

Medicines

Product	Units/Dose	Units	Doses/Day	Num Days	% Treated	Units/Episode	Episode Cost
Didanosine [Videx] 50MG/tab	2.0	tab	2	365	75.0%	1,095.0	262.12 US
Didanosine 100MG/tab	1.0	tab	2	365	100.0%	730.0	185.17 US
Didanosine 25MG/tab	1.0	tab	2	365	25.0%	182.5	43.41 US
Lopinavir-Ritonavir [Aluvia] 200+50MG/tab	2.0	tab	2	365	100.0%	1,460.0	500.05 US
Stavudine 30MG/cap	1.0	cap	2	365	100.0%	730.0	69.35 US
						1,060.10	US

Pricing	Central Medical Stores		US
	Medicines	Supply Items	Total
1 Episode	1,060.10	0.00	1,060.10
Data Set	0.00	0.00	0.00